Wetenschappelijk onderzoek over de behandeling van overgangsklachten

Het protocol voor de behandeling van overgangsklachten is op basis van wetenschappelijke publicaties ontwikkeld. Hierbij is gebruik gemaakt van hoog gekwalificerd recent onderzoek dat wordt gepubliceerd in de PubMed database. placebo controlled onderzoek, meta analyses en reviews hebben de voorkeur. Dit soort onderzoek valt onder Evidence Based Medicine.

Welkom op deze website Alles over de ziekte Alles over de behandeling Gratis suplementadvies

Pathology

National Library of Medicine (PubMed)
  1. Wikipedia Opvlieger
    Een opvlieger ontstaat doordat het temperatuurcentrum (of warmtecentrum) in de hersenen ontregeld raakt door onbekende oorzaak. Het centrum heeft onder normale omstandigheden een zekere tolerantiemarge van viertiende graad waarbinnen temperatuurschommelingen worden toegelaten. Bij vrouwen met opvliegers is die marge versmald, waardoor zij het snel te warm hebben. Het lichaam wil de warmte zo snel mogelijk kwijt en zorgt dat de bloedvaten in de huid zich verwijden en de opvlieger is een feit.[/fusion_builder_column]
    [Article]
  2. Wulf H. Utian Current Obstetrics and Gynecology Reports June 2012, Volume 1, Issue 2, pp 43-49 Recent Developments in Pharmacotherapy for Vasomotor Symptom
    Many women experience vasomotor symptoms (VMS) at or around the time of menopause. Hot flashes and night sweats are considered primary menopausal symptoms that may also be associated with sleep and mood disturbances, as well as decreased cognitive function.[Article]
  3. International Menopause Society – Menopause Terminology
    Throughout the world, misuse of terminology related to the field of menopause has caused a great deal of confusion and misinformation among healthcare providers, those in research, the media, and the public. To help ensure a standardized definition of key words used in the field, the International Menopause Society (IMS) commissioned a project through its sub-organ, the Council of Affiliated Menopause Societies (CAMS).[Article]
  4. Causes By Mayo Clinic Staff
    Menopause can result from.[Article]

  5. .[Abstract]

Oorzaken en gevolgen van de menopauze

    Medische ingreep

  1. Lammerink EA, de Bock GH, Schröder CP, Mourits MJ. Maturitas. 2012 Nov;73(3):265-8. doi: 10.1016/j.maturitas.2012.07.010. The management of menopausal symptoms in breast cancer survivors: case-based approach
    The main side-effects, such as vasomotor symptoms and impaired sexual functioning, are related to premature menopause due to chemotherapy and/or anti-hormonal therapy.[Article]
  2. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Clin Ther. 2007 Feb;29(2):230-41. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review
    Women with breast cancer may experience treatment-induced menopausal symptoms or natural menopause.[Article]
  3. Torino F, Barnabei A, De Vecchis L, Appetecchia M, Strigari L, Corsello SM. Endocr Relat Cancer. 2012 Apr 10;19(2):R21-33. doi: 10.1530/ERC-11-0199. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer
    Cytotoxic anticancer treatment may induce amenorrhea or menopause to a variable extent.[Article]
  4. Desmarais JE, Looper KJ. Maturitas. 2010 Dec;67(4):296-308. doi: 10.1016/j.maturitas.2010.08.005. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions
    Tamoxifen, a medication used in the treatment of breast cancer, often induces menopausal symptoms.[Article]
  5. Fichera M, Rinaldi N, Tarascio M, Taschetta S, Caldaci LM, Catavorello A, La Rosa B, Panella MM. Minerva Ginecol. 2013 Jun;65(3):331-44. Indications and controindications of hormone replacement therapy in menopause
    Menopause occurs when the functional ovarian reserve is exhausted or can be induced by surgical removal of the ovaries.[Abstract]
  6. Weinstein L. Obstet Gynecol. 1990 Apr;75(4 Suppl):47S-50S; discussion 51S-52S. Hormonal therapy in the patient with surgical menopause
    Removal of both ovaries in the premenopausal patient is performed infrequently, but when it is, attention must be paid to hormone replacement..[Abstract]
  7. Reich H. J Reprod Med. 2001 Mar;46(3 Suppl):297-306. Issues surrounding surgical menopause. Indications and procedures
    physicians should consider the surgical techniques available, the impact of ovary removal and the subsequent induction of menopause, and the requirement of long-term estrogen replacement.[Abstract]
  8. AMC: Het verwijderen van eierstokken
    In overleg met uw arts worden hormoonvervangende medicijnen voorgeschreven.[Abstract]
  9. Osteoporose

    REVIEW
  10. Väänänen HK, Härkönen PL. Maturitas. 1996 May;23 Suppl:S65-9.Estrogen and bone metabolism
    Estrogen plays an important role in the growth and maturation of bone as well as in the regulation of bone turnover in adult bone. During bone growth estrogen is needed for proper closure of epiphyseal growth plates both in females and in males.[Abstract]
  11. Faienza MF, Ventura A, Marzano F, Cavallo L. Clin Dev Immunol. 2013;2013:575936. doi: 10.1155/2013/575936. Postmenopausal osteoporosis: the role of immune system cells
    The combined effects of estrogen deprivation and raising of FSH production occurring in menopause cause a marked stimulation of bone resorption and a rapid bone loss which is central for the onset of postmenopausal osteoporosis.[Article]
  12. ESHRE Capri Workshop Group. Hum Reprod Update. 2010 Nov-Dec;16(6):761-73. doi: 10.1093/humupd/dmq008. Bone fractures after menopause
    Ageing reduces bone strength in post-menopausal women because estrogen deficiency causes accelerated bone resorption.[Article]
  13. Mundy GR. Nutr Rev. 2007 Dec;65(12 Pt 2):S147- Osteoporosis and inflammatio
    Human and animal experiments have implicated pro-inflammatory cytokines as primary mediators of the accelerated bone loss at menopause including interleukin-1, tumor necrosis factor-alpha, and interleukin-6. Increased production of pro-inflammatory cytokines is associated with osteoclastic bone resorption in a number of disease states including rheumatoid arthritis, periodontitis, and multiple myeloma; estrogen withdrawal is associated with increased production of pro-inflammatory cytokines.[Abstract]
  14. D’Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G. Bone. 2008 Jul;43(1):92-100. doi: 10.1016/j.bone.2008.02.017. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis
    Women with post-menopausal osteoporosis have a higher T cell activity than healthy post-menopausal subjects; T cells thus contribute to the bone loss induced by estrogen deficiency in humans as they do in the mouse.[Article]
  15. Schnatz PF, Marakovits KA, O’Sullivan DM. Obstet Gynecol Surv. 2010 Sep;65(9):591-6. doi: 10.1097/OGX.0b013e3181fc6d30. Assessment of postmenopausal women and significant risk factors for osteoporosis
    Our results also suggest that a history of pregnancy and breast-feeding protects against the development of postmenopausal osteoporosis, especially in women aged 49 to 54.[Abstract]
  16. Hart en vaatziekten

    REVIEW
  17. Masood DE, Roach EC, Beauregard KG, Khalil RA. Curr Drug Metab. 2010 Oct;11(8):693-714. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular diseas
    Epidemiological studies have shown that cardiovascular disease (CVD) is less common in pre-menopausal women (Pre-MW) compared to men of the same age or post-menopausal women (Post-MW), suggesting cardiovascular benefits of estrogen.[Article]
  18. Stevenson JC. Maturitas. 2011 Oct;70(2):197-205. doi: 10.1016/j.maturitas.2011.05.017. A woman’s journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement.
    However, the onset of menopause and the loss of ovarian function is associated with a significant increase in the prevalence of diseases such as coronary heart disease, osteoarthritis and osteoporosis.[Article]
  19. Kallen AN, Pal L. Curr Opin Obstet Gynecol. 2011 Aug;23(4):258-67. doi: 10.1097/GCO.0b013e3283488a21. Cardiovascular disease and ovarian function
    Ovarian hormones modulate the processes of atherosclerosis and the mechanisms underlying CHD. The female reproductive hormones offer a cardioprotective milieu that is rapidly attenuated with the cessation of ovarian function (be it following natural menopause or after medical or surgical ovarian extirpation).[Abstract]
  20. META
  21. Spoletini I, Vitale C, Rosano GM. Biomark Med. 2011 Aug;5(4):485-95. doi: 10.2217/bmm.11.51. Biomarkers for predicting postmenopausal coronary heart disease
    Coronary heart disease (CHD) is the main cause of death in post-menopausal women (PMW). Beyond the ‘traditional’ cardiovascular risk factors of CHD, newer biomarkers, reflecting inflammation, endothelial function and oxidative stress, have received growing consideration. We systematically reviewed the literature on the biomarkers for predicting CHD in PMW. C-reactive protein, IL-6 and Lipoprotein (a) have been consistently found to be associated with CHD risk in PMW.[Abstract]
  22. Borstkanker

    META
  23. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet Oncol. 2012 Nov;13(11):1141-51. doi: 10.1016/S1470-2045(12)70425-4. E Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
    Breast cancer risk increased by a factor of 1·050 (95% CI 1·044-1·057; p<0·0001) for every year younger at menarche, and independently by a smaller amount (1·029, 1·025-1·032; p<0·0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1·43, 1·33-1·52, p<0·001).[Article]
  24. Taylor VH, Misra M, Mukherjee SD. Breast Cancer Res Treat. 2009 Sep;117(1):1-8. doi: 10.1007/s10549-009-0441-y. Is red meat intake a risk factor for breast cancer among premenopausal women?
    The summary relative risk was 1.24 (95% CI 1.08-1.42). Case-control studies (N = 7) had a risk of 1.57 (95% CI 1.23-1.99), while cohort studies (N = 3) had a summary relative risk of 1.11 (95% CI 0.94-1.31).[Abstract]
  25. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. PLoS One. 2012;7(12):e51446. doi: 10.1371/journal.pone.0051446. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis
    The results of this meta-analysis showed that body mass index has no significant effect on the incidence of breast cancer during premenopausal period. On the other hand, overweight and obesity may have a minimal effect on breast cancer, although significant, but really small and not clinically so important.[Article]
  26. Connolly BS, Barnett C, Vogt KN, Li T, Stone J, Boyd NF. Nutr Cancer. 2002;44(2):127-38. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer
    This meta-analysis indicates that a greater WHR is associated with increased risk of breast cancer and suggests that the avoidance of abdominal obesity may reduce risk of the disease.[Abstract]
  27. REVIEW
  28. Turck D; Comité de nutrition de la Société française de pédiatrie. Arch Pediatr. 2005 Dec;12 Suppl 3:S145-65. Breast feeding: health benefits for child and mother
    Breastfeeding is also associated with a decreased risk of breast and ovarian cancer in the premenopausal period, and of hip fractures and osteoporosis in the postmenopausal period.[Abstract]
  29. Overgewicht

    REVIEW – OBESITY
  30. Simkin-Silverman LR, Wing RR. Postgrad Med. 2000 Sep 1;108(3):47-50, 53-6. Weight gain during menopause. Is it inevitable or can it be prevented?
    The years surrounding the menopause are associated with weight gain, increased central adiposity, and decreased physical activity. While weight change occurs independent of menopausal status, adverse changes in body fat distribution and body composition may be due to hormonal changes occurring during the menopausal transition.[Abstract]
  31. Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi RE, Shah D, Villaseca P; Writing Group of the International Menopause Society for World Menopause Day 2012. Climacteric. 2012 Oct;15(5):419-29. doi: 10.3109/13697137.2012.707385. Understanding weight gain at menopause
    The hormonal changes across the perimenopause substantially contribute to increased abdominal obesity which leads to additional physical and psychological morbidity.[Abstract]
  32. REVIEW – IR
  33. Savva SC, Lamnisos D, Kafatos AG. Diabetes Metab Syndr Obes. 2013 Oct 24;6:403-419. eCollection 2013. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis
    WHtR was found to have a stronger association than BMI with diabetes mellitus (rRR: 0.71, 95% CI: 0.59-0.84) and metabolic syndrome.[Article]
  34. Mendes KG, Theodoro H, Rodrigues AD, Olinto MT. Cad Saude Publica. 2012 Aug;28(8):1423-37. Prevalence of metabolic syndrome and its components in the menopausal transition: a systematic review
    Based on the selected studies, prevalence of metabolic syndrome increases in the post-menopausal (as compared to pre-menopausal) period, regardless of the population and study design. The change was more significant for waist circumference and blood pressure, suggesting that these components have the greatest influence on prevalence of metabolic syndrome.[Abstract]
  35. Whitcroft S, Herriot A. Menopause Int. 2011 Mar;17(1):24-8. doi: 10.1258/mi.2011.011003. Insulin resistance and management of the menopause: a clinical hypothesis in practice
    Insulin resistance (IR) is associated with a number of metabolic abnormalities including glucose intolerance, dyslipidemia and central obesity (the metabolic syndrome), which predispose to cardiovascular disease, diabetes mellitus and some cancers. The incidence of many of these conditions increases after the menopause, a time when IR also increases.[Abstract]
  36. Polotsky HN, Polotsky AJ. Semin Reprod Med. 2010 Sep;28(5):426-34. doi: 10.1055/s-0030-1262902. Metabolic implications of menopause
    The incidence of metabolic syndrome increases substantially during perimenopause and early menopause.[Abstract]
  37. Ross LA, Polotsky AJ. Curr Opin Obstet Gynecol. 2012 Dec;24(6):402-7. doi: 10.1097/GCO.0b013e32835a91bc. Metabolic correlates of menopause: an update
    Over a quarter of the US population is affected by metabolic disease at midlife, and some studies have shown that the incidence of MetS increases with menopause.[Abstract]
  38. Lobo RA. Maturitas. 2008 May 20;60(1):10-8. doi: 10.1016/j.maturitas.2008.02.008. Metabolic syndrome after menopause and the role of hormones
    MBS may occur in 40% of PM women and is largely determined by overweight status and obesity.[Abstract]
  39. Carr MC. J Clin Endocrinol Metab. 2003 Jun;88(6):2404-11. The emergence of the metabolic syndrome with menopause
    The prevalence of the metabolic syndrome increases with menopause and may partially explain the apparent acceleration in CVD after menopause.[Article]
  40. REVIEW – verzadiging
  41. Butera PC. Physiol Behav. 2010 Feb 9;99(2):175-80. doi: 10.1016/j.physbeh.2009.06.010. Estradiol and the control of food intake
    A key role of estradiol in the control of food intake and energy balance in humans is evidenced by the fact that the incidence of obesity increases greatly after menopause.[Article]
  42. Geary N. Peptides. 2001 Aug;22(8):1251-63. Estradiol, CCK and satiation
    Experimental manipulations of exogenous and endogenous CCK and estradiol have produced converging evidence that estradiol cyclically increases the activity of the CCK satiation-signaling pathway so that meal size and food intake decrease during the ovulatory or estrus phase of the ovarian cycle.[Abstract]
  43. Eckel LA. Physiol Behav. 2011 Sep 26;104(4):517-24. doi: 10.1016/j.physbeh.2011.04.014. The ovarian hormone estradiol plays a crucial role in the control of food intake in females
    Adult female rats display a robust decrease in food intake during estrus and ovariectomy promotes hyperphagia and weight gain, both of which can be prevented by a physiological regimen of estradiol treatment.[Article]
  44. Geary N. Medscape Womens Health. 1998 Nov;3(6):3. The effect of estrogen on appetite
    Furthermore, accumulating evidence indicates that estradiol may decrease meal size by increasing the potency of the satiating actions of some gut peptides, especially cholecystokinin.[Abstract]
  45. REVIEW – verbranding
  46. Poehlman ET. Acta Obstet Gynecol Scand. 2002 Jul;81(7):603-11. Menopause, energy expenditure, and body composition
    Preliminary evidence suggests that natural menopause is associated with reduced energy expenditure during rest and physical activity, an accelerated loss of fat-free mass, and increased central adiposity and fasting insulin levels.[Abstract]
  47. Poehlman ET, Tchernof A. Coron Artery Dis. 1998;9(12):799-803. Traversing the menopause: changes in energy expenditure and body composition
    Thus, it appears that the loss of ovarian function induces a reduction in resting metabolic rate, physical activity energy expenditure, fat-free mass, and an increase in fat mass and abdominal adipose tissue accumulation.[Abstract]
  48. Nog niet gebruikte artikelen


  49. .[Abstract]

  50. .[Abstract]

Reguliere behandeling

    Hormoontherapie

  1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators. JAMA. 2002 Jul 17;288(3):321-33. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial

    Estrogen plus progestin component of the Women’s Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998.

    On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits.

    Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases;

    [Article]
  2. REVIEW
  3. Fournier A1, Hill C, Clavel-Chapelon F. Bull Cancer. 2003 Oct;90(10):821-31. Hormone replacement therapy in menopause and risk of breast cancer
    The accumulated evidence shows a higher risk of breast cancer among HRT ever users compared to non users. The risk increases with treatment duration and disappears a few years after the end of the treatment.[Abstract]
  4. META
  5. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA; Cochrane HT Study Group. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004143. Long term hormone therapy for perimenopausal and postmenopausal women
    In relatively healthy women, combined continuous HT significantly increased the risk of venous thromboembolism or coronary event (after one year’s use), stroke (after 3 years), breast cancer (after 5 years) and gallbladder disease. Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease. Overall, the only statistically significant benefits of HT were a decreased incidence of fractures and colon cancer with long-term use.[Abstract]
  6. META
  7. Greiser CM1, Greiser EM, Dören M. Hum Reprod Update. 2005 Nov-Dec;11(6):561-73. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
    In conclusion, there is evidence that relative risks for BC risks by MHT, in particular EPT, have been increasing in recent years.[Article]
  8. META
  9. Greiser CM, Greiser EM, Dören M. Hum Reprod Update. 2007 Sep-Oct;13(5):453-63. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis
    The risk of OvC (ever-use, annual risk) is increased 1.28-fold by ET [confidence interval (CI) 1.18-1.40] and 1.11-fold by EPT (CI 1.02-1.21) with a suggestion of greater risks with ET.[Article]
  10. META
  11. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. BMJ. 2008 May 31;336(7655):1227-31. doi: 10.1136/bmj.39555.441944.BE. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
    Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment.[Article]
  12. META
  13. Greiser CM, Greiser EM, Dören M. Maturitas. 2010 Mar;65(3):198-204. doi: 10.1016/j.maturitas.2009.11.027.
    We found a significant increase of risk – 76.2% – in non-smoking women with adenocarcinoma reporting ever-use of HT. Estrogen plus progestin therapy does not change the risk; however.[Abstract]
  14. RCT
  15. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O’Sullivan MJ, Ockene JK, Chen C, Hubbell FA; Women’s Health Initiative Investigators. Lancet. 2009 Oct 10;374(9697):1243-51. doi: 10.1016/S0140-6736(09)61526-9. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial
    Although treatment with oestrogen plus progestin in postmenopausal women did not increase incidence of lung cancer, it increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer. These findings should be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer.[Article]
  16. META
  17. Pearce CL, Chung K, Pike MC, Wu AH. Cancer. 2009 Feb 1;115(3):531-9. doi: 10.1002/cncr.2395 Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin
    ET use increases risk of ovarian cancer in a duration-dependent manner, and it appears that the addition of progestins blocks this effect, at least to some extent. Whether the effect of estrogens would be completely blocked if progestins were given every day is unclear.[Abstract]
  18. REVIEW
  19. Prentice RL1. Semin Reprod Med. 2014 Nov;32(6):419-25. doi: 10.1055/s-0034-1384624. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke
    Specifically, with combined estrogen plus progestin, CHD risk was elevated early with the elevation dissipating after a few years of treatment, whereas breast cancer elevations increased during the treatment period, and climbed to about a threefold increase following 5 years of adherence. Importantly, breast cancer risk elevations appear to be higher among women who initiate treatment at the menopause, or soon thereafter, compared with women having a longer gap time.[Article]
  20. REVIEW
  21. Chlebowski RT1, Anderson GL2. Steroids. 2014 Nov;90:53-9. doi: 10.1016/j.steroids.2014.06.001. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.
    In these trials, estrogen plus progestin significantly increased breast cancer incidence and deaths from breast cancer, significantly increased deaths from lung cancer, significantly decreased endometrial cancer, and did not have a clinically significant influence on colorectal cancer. In contrast, estrogen alone use in women with prior hysterectomy significantly reduced breast cancer incidence and deaths from breast cancer without significant influence on colorectal cancer or lung cancer.[Article]
  22. REVIEW
  23. Gurney EP1, Nachtigall MJ1, Nachtigall LE1, Naftolin F2. J Steroid Biochem Mol Biol. 2014 Jul;142:4-11. doi: 10.1016/j.jsbmb.2013.10.009 The Women’s Health Initiative trial and related studies: 10 years later: a clinician’s view
    In this paper, we review data supporting the use of HT administered to postmenopausal women, showing it to have more benefit than risk for symptom control, prevention of bone mineral loss and fracture, and improvement of the metabolic profile in women who began HT when they were less than 60 years of age and had their last menstrual period less than ten years previous.[Abstract]
  24. META
  25. Benson VS1, Kirichek O, Beral V, Green J. Int J Cancer. 2015 May 15;136(10):2369-77. doi: 10.1002/ijc.29274. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis
    The totality of the available evidence suggests an increased risk of all CNS tumors (and of glioma and meningioma separately) in users of estrogen-only HT. Absolute excess risk (2 per 10,000 users over 5 years) is small.[Abstract]
  26. META
  27. Qi ZY1, Shao C1, Huang YL1, Hui GZ1, Zhou YX1, Wang Z1. PLoS One. 2013 Dec 27;8(12):e83261. doi: 10.1371/journal.pone.0083261. eCollection 2013. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis
    In conclusion, the results of our study support the hypothesis that longer exposure to effect of female sex hormones may increase the risk of meningioma in women, yet additional studies are warranted to confirm our findings and identify the underlying biological mechanisms..[Article]
  28. Gu H1, Zhao X, Zhao X, Yang Y, Lv X. Menopause. 2014 Nov;21(11):1204-10. doi: 10.1097/GME.0000000000000227. Risk of stroke in healthy postmenopausal women during and after hormone therapy: a meta-analysis
    These findings suggest that HT may increase the risk of stroke during, but not after, HT in healthy postmenopausal women.[Abstract]
  29. NHG-Standaard De overgang
    Systemisch toegediende oestrogenen verminderen vasomotorische klachten het meest effectief.26) Ze hebben echter ook bijwerkingen, zoals verhoging van het risico op veneuze trombo-embolie, mammacarcinoom en cardiovasculaire aandoeningen, om welke reden ze (relatief) gecontra-indiceerd kunnen zijn (kader).27-31) Bespreek met de vrouw dat de bijwerkingen van hormoontherapie relatief zeldzaam zijn, maar wel potentieel zeer ernstig, en dat deze therapie wordt voorgeschreven voor weliswaar zeer hinderlijke maar niet levensbedreigende klachten.[Article]
  30. Global consensus HRT

  31. de Villiers TJ1, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Climacteric. 2013 Apr;16(2):203-4. doi: 10.3109/13697137.2013.771520. Global consensus statement on menopausal hormone therapy
    More than ten years after the publication of the “Women’s Health Initiatives” (WHI) study, a global consensus statement on menopausal hormone replacement therapy (HRT) has been edited by an expert committee, composed by all the international menopausal societies. This global consensus has been published in April 2013 in the journal Climacteric. In conclusion, HRT has to be an individual decision, weighing up benefits and risks and it should not be prescribed for the first time in women older than 60 years or more than ten years after the onset of menopause. Dose and duration of HRT are individual and the indication has to be reevaluated annually. HRT is contraindicated in breast cancer survivors.[Article]
  32. Bioidentical HRT

    bio-HRT does not mean natural

    REVIEW
  33. Sites CK1. Womens Health (Lond Engl). 2008 Mar;4(2):163-71. doi: 10.2217/17455057.4.2.163. Bioidentical hormones for menopausal therapy
    ‘Bioidentical hormones’ is a term created by the lay media to refer to chemicals derived from plants that are modified to be structurally identical to endogenous human hormones.[Abstract]
  34. REVIEW
  35. Cirigliano M J Womens Health (Larchmt). 2007 Jun;16(5):600-31. Bioidentical hormone therapy: a review of the evidence
    Bioidentical hormone therapy (BHT) uses bioidentical hormones (BHs), derivatives of plant extracts chemically modified to be structurally indistinguishable from human endogenous hormones.[Abstract]
  36. Iftikhar S1, Shuster LT, Johnson RE, Jenkins SM, Wahner-Roedler DL. J Womens Health (Larchmt). 2011 Apr;20(4):559-65. doi: 10.1089/jwh.2009.1915. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center.
    Visits to health care providers for menopausal symptoms are ideal for physicians to educate women that in the absence of data to the contrary, BCH should be considered to have the same risks as CHT.[Abstract]
  37. OTHER
  38. Fishman JR1, Flatt MA2, Settersten RA Jr3. Soc Sci Med. 2015 May;132:79-87. doi: 10.1016/j.socscimed.2015.02.027. Epub 2015 Feb 19. Bioidentical hormones, menopausal women, and the lure of the “natural” in U.S. anti-aging medicine
    The attraction to and promise of BHRT is rooted in the idea that it is a “natural” therapy. BHRT is given both biomedical and embodied legitimacy by clinicians and patients because of its purported ability to become part of the body’s “natural” processes. The normative assumption that “natural” is inherently “good” not only places BHRT beyond reproach, but transforms its use into a health benefit. [Abstract]
  39. Lack of safety data bio-HRT

    OTHER
  40. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; American Society for Reproductive Medicine Practice Committee. Fertil Steril. 2012 Aug;98(2):308-12. Compounded bioidentical menopausal hormone therapy
    Not only is evidence lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy, but these claims also pose the additional risks of variable purity and potency and lack efficacy and safety data.[Article]
  41. REVIEW
  42. Davis R1, Batur P, Thacker HL. J Womens Health (Larchmt). 2014 Aug;23(8):642-8. doi: 10.1089/jwh.2014.4770. Risks and effectiveness of compounded bioidentical hormone therapy: a case series
    The media and celebrity endorsements have promoted a number of misconceptions about the risks and benefits associated with the various forms of BHT. Due to the lack of sufficient data to support the efficacy or safety of BHT, we recommend the use of United States Food and Drug Administration-approved regimens in the management of menopausal symptoms. [Abstract]
  43. REVIEW
  44. Huntley AL1. Menopause Int. 2011 Mar;17(1):16-8. doi: 10.1258/mi.2011.011009. Compounded or confused? Bioidentical hormones and menopausal health
    The practice of compounding BHs for individualized treatment of women with menopausal symptoms has developed in the USA. In spite of claims of superiority, there is no evidence to suggest that these formulations are any more efficacious or safe than conventional hormone replacement therapy (HRT).[Abstract]
  45. REVIEW
  46. Cirigliano M1. J Womens Health (Larchmt). 2007 Jun;16(5):600-31. Bioidentical hormone therapy: a review of the evidence.
    Compounded BHTs have been promoted by some as natural, safer, and in some cases more efficacious than conventional hormone therapies, but there is a dearth of scientific evidence to support these claims. Compounded BHTs lack well controlled studies examining route of administration, pharmacokinetics, safety, and a critical, science-based rationale for the mixture and ratios of bioidentical estrogens employed in many preparations.[Abstract]
  47. OTHER
  48. Fugh-Berman A1, Bythrow J. J Gen Intern Med. 2007 Jul;22(7):1030-4. Epub 2007 Mar 7. Bioidentical hormones for menopausal hormone therapy: variation on a theme
    Natural hormones, including estradiol, estriol, estrone, and progesterone, can be expected to have the same adverse event profile as conventional menopausal hormone regimens.[Abstract]
  49. bio-HRT veilig?

  50. Holtorf K1. Postgrad Med. 2009 Jan;121(1):73-85. doi: 10.3810/pgm.2009.01.1949. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Physiological data and clinical outcomes demonstrate that bioidentical hormones are associated with lower risks, including the risk of breast cancer and cardiovascular disease, and are more efficacious than their synthetic and animal-derived counterparts. Until evidence is found to the contrary, bioidentical hormones remain the preferred method of HRT.[Abstract]
  51. REVIEW
  52. Moskowitz D. Altern Med Rev. 2006 Sep;11(3):208-23. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks
    The studies reviewed suggest bioidentical progesterone does not have a negative effect on blood lipids or vasculature as do many synthetic progestins, and may carry less risk with respect to breast cancer incidence. Studies of both bioidentical estrogens and progesterone suggest a reduced risk of blood clots compared to non-bioidentical preparations.[Article]
  53. Gabapentine

  54. Wikipedia Gabapentine
    Gabapentine is een geneesmiddel uit de groep van anti-epileptica. Het is een GABA-agonist met een chemische structuur gelijkt op die van de neurotransmitter GABA (gamma-aminoboterzuur).[Article]
  55. Medicijn: Gabapentine
    De werkzame stof in Gabapentine is gabapentine. Gabapentine beïnvloedt de informatieoverdracht via zenuwen in de hersenen. Artsen schrijven het voor bij bepaalde vormen van epilepsie en bij zenuwpijn. Soms wordt het gebruikt bij het pijnsyndroom posttraumatische dystrofie, bij hik en spierkrampen.[Article]
  56. META
  57. Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Clin Ther. 2009 Feb;31(2):221-35. doi: 10.1016/j.clinthera.2009.02.006. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis
    Comparisons of gabapentin and placebo revealed reductions of 20% to 30% in the frequency and severity of hot flashes with gabapentin, although data across the studies were too heterogeneous to provide a reliable summary effect.[Abstract]
  58. RCT
  59. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Lancet. 2005 Sep 3-9;366(9488):818-24. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial
    Gabapentin is effective in the control of hot flashes at a dose of 900 mg/day, but not at a dose of 300 mg/day. This drug should be considered for treatment of hot flashes in women with breast cancer.[Article]
  60. Saadati N, Mohammadjafari R, Natanj S, Abedi P. Glob J Health Sci. 2013 Sep 10;5(6):126-30. doi: 10.5539/gjhs.v5n6p126. The effect of gabapentin on intensity and duration of hot flashes in postmenopausal women: a randomized controlled trial
    According to the findings of this study; it appears that the use of gabapentin could decrease the intensity, duration and frequency of hot flashes in postmenopausal women. For postmenopausal women who hormone therapy is contraindicated, gabapentine could be an acceptable alternative.[Abstract]
  61. Cowles VE, Gordi T, Hou SY. Clin Drug Investig. 2012 Sep 1;32(9):593-601. doi: 10.2165/11634520-000000000-00000. Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms
    The pharmacokinetic profile of gabapentin-ER may allow for once- or twice-daily dosing while maintaining bioavailability and thus efficacy. Gabapentin-ER was well tolerated.[Abstract]
  62. Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gynecol Endocrinol. 2010 May;26(5):333-7. doi: 10.3109/09513590903511539. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes
    Despite statistical significant differences, from a clinical point of view oral GPT 600 mg was as effective as low-dose transdermal E(2) in controlling moderate to severe hot flushes in post-menopausal women, and should be recommended as an alternative option in those with contraindications to estrogen therapy. More research is warranted in this regard.[Abstract]
  63. Biglia N, Sgandurra P, Peano E, Marenco D, Moggio G, Bounous V, Tomasi Cont N, Ponzone R, Sismondi P. Climacteric. 2009 Aug;12(4):310-8. doi: 10.1080/13697130902736921. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E
    Gabapentin appears to be effective for the treatment of hot flushes with a favorable effect on quality of sleep. Vitamin E has only marginal effect on vasomotor symptoms.[Abstract]
  64. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Menopause. 2008 Mar-Apr;15(2):310-8. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial
    Gabapentin at 900 mg/day is an effective and well-tolerated treatment for hot flashes.[Abstract]
  65. Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, Guzick DS. Obstet Gynecol. 2006 Jul;108(1):41-8. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial
    Despite the small scale of this study, gabapentin appears to be as effective as estrogen in the treatment of postmenopausal hot flushes.[Abstract]
  66. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Obstet Gynecol. 2003 Feb;101(2):337-45. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial
    Gabapentin is effective in reducing hot flash frequency and severity in postmenopausal women.[Abstract]
  67. Pregabalin

    RCT
  68. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM Jr, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. J Clin Oncol. 2010 Feb 1;28(4):641-7. doi: 10.1200/JCO.2009.24.5647. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1
    Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.[Article]
  69. Antidepressiva

    REVIEW
  70. Imai A, Matsunami K, Takagi H, Ichigo S. Gynecol Endocrinol. 2013 Jan;29(1):63-6. doi: 10.3109/09513590.2012.705380. New generation nonhormonal management for hot flashes
    Several nonhormonal therapies have been tested in randomized placebo-controlled trials including nonpharmacologic approaches and pharmacologic nonhormonal agents. Among them, two classes of nonhormonal medications have been demonstrated to effectively alleviate hot flashes: ?-aminobutyric acid (GABA) analogs and selective serotonin reuptake inhibitors (SSRIs). [Abstract]
  71. META
  72. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. JAMA. 2006 May 3;295(17):2057-71. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis
    The SSRIs or SNRIs, clonidine, and gabapentin trials provide evidence for efficacy; however, effects are less than for estrogen, few trials have been published and most have methodological deficiencies, generalizability is limited, and adverse effects and cost may restrict use for many women. These therapies may be most useful for highly symptomatic women who cannot take estrogen but are not optimal choices for most women.[Article]
  73. Rexflavone

    RCT
  74. Lee J, Kim KW, Kim HK, Chae SW, Jung JC, Kwon SH, Rheu CH. Arch Pharm Res. 2010 Apr;33(4):523-30. doi: 10.1007/s12272-010-0405-0. The effect of Rexflavone (Sophorae fructus extract) on menopausal symptoms in postmenopausal women: a randomized double-blind placebo controlled clinical trial
    It was shown that the consumption of Rexflavone possessed beneficial effects on the postmenopausal symptoms in postmenopausal women.[Abstract]
  75. OTHER
  76. Joo SS, Kwon SH, Hwang KW, Lee DI. Arch Pharm Res. 2005 May;28(5):566-72. Improvement of menopausal signs by isoflavones derived from Sophorae fructus in ovariectomized female rats and the antioxidant potentials in BV2 cells
    In conclusion, this study highlights the anti-menopausal and antioxidant effect of SISO in an ovariectomized rat model, as well as in microglial cells, and provides new clinical targets for the screening of phytoestrogens as potential candidates for HRT in menopausal women.[Abstract]

  77. .[Abstract]

  78. .[Abstract]

  79. .[Abstract]

Behandeling menopauzeklachten met Isoflavonen

    MENOPAUSAL SYMPTOMS

    META
  1. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Menopause. 2012 Jul;19(7):776-90. doi: 10.1097/gme.0b013e3182410159. xtracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials
    Soy isoflavone supplements, derived by extraction or chemical synthesis, are significantly more effective than placebo in reducing the frequency and severity of hot flashes.[Abstract]
  2. Hum Reprod Update. 2009 Jul-Aug;15(4):423-40. doi: 10.1093/humupd/dmp010. Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, Cassidy A. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis
    Isoflavone-rich soy products decrease FSH and LH in premenopausal women and may increase estradiol in post-menopausal women. The clinical implications of these modest hormonal changes remain to be determined.[Article]
  3. Bolaños R, Del Castillo A, Francia J. Menopause. 2010 May-Jun;17(3):660-6. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis
    Although the overall combined results and the results by subgroups (according to the type of supplement used) showed a significant tendency in favor of soy, it is still difficult to establish conclusive results given the high heterogeneity found in the studies.[Abstract]
  4. RCT
  5. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Maturitas. 2007 Nov 20;58(3):249-58. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study
    The soy isoflavone extract exerted favorable effects on vasomotor symptoms and good compliance, providing a safe and effective alternative therapeutic for postmenopausal women.[Abstract]
  6. Li Y, Liu K, Lei W, Zhang K. Wei Sheng Yan Jiu. 2010 Jan;39(1):56-9. Effect of soy isoflavones on peri-menopausal symptom and estrogen
    Menopausal symptoms and the secretion of estrogen were improved in peri-menopausal women on a daily dosage of 120 mg of soy isoflavone.[Abstract]
  7. Ferrari A. J Obstet Gynaecol Res. 2009 Dec;35(6):1083-90. doi: 10.1111/j.1447-0756.2009.01058.x. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms
    In daily practice conditions, high doses of isoflavones, particularly genistein, can be used for the management of hot flushes in postmenopausal women not treated with hormone replacement therapy due to their superior efficacy to placebo and very good safety profile.[Abstract]
  8. Albertazzi P, Steel SA, Bottazzi M. Climacteric. 2005 Dec;8(4):371-9. Effect of pure genistein on bone markers and hot flusheshttp://www.ncbi.nlm.nih.gov/pubmed/16390772
    Pure genistein at a dose of 90 mg per day appears to reduce the number of hot flushes in postmenopausal women but the effect is mild.[Abstract]
  9. Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. Maturitas. 2011 Feb;68(2):189-96. doi: 10.1016/j.maturitas.2010.11.012. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study
    The current study provides the first evidence that a single daily dose of 30 mg of synthetic genistein reduces hot flush frequency and duration.[Abstract]
  10. D’Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F, Triolo O, Rizzo P, Russo S, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Adamo EB, Squadrito F. Menopause. 2009 Mar-Apr;16(2):301-6. doi: 10.1097/gme.0b013e318186d7e2. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study
    The phytoestrogen genistein has been shown to be effective on vasomotor symptoms without an adverse effect on the endometrium and vagina, but after the first year, there was no further improvement in the decrease in hot flushes.[Abstract]
  11. Albertazzi P, Steel SA, Bottazzi M. Climacteric. 2005 Dec;8(4):371-9. Effect of pure genistein on bone markers and hot flushes
    Pure genistein at a dose of 90 mg per day appears to reduce the number of hot flushes in postmenopausal women but the effect is mild.[Abstract]
  12. Welty FK, Lee KS, Lew NS, Nasca M, Zhou JR. J Womens Health (Larchmt). 2007 Apr;16(3):361-9. The association between soy nut consumption and decreased menopausal symptoms
    Substituting soy nuts for nonsoy protein in a TLC diet and consumed three or four times throughout the day is associated with a decrease in hot flashes and improvement in menopausal symptoms.[Article]
  13. Yang TS, Wang SY, Yang YC, Su CH, Lee FK, Chen SC, Tseng CY, Jou HJ, Huang JP, Huang KE. Taiwan J Obstet Gynecol. 2012 Jun;51(2):229-35. doi: 10.1016/j.tjog.2012.04.011. Effects of standardized phytoestrogen on Taiwanese menopausal women
    Soy extract is highly efficacious at relieving menopausal symptoms and demonstrates a positive effect on the cardiovascular system and skeleton.[Abstract]
  14. CLINICAL
  15. Jenks BH, Iwashita S, Nakagawa Y, Ragland K, Lee J, Carson WH, Ueno T, Uchiyama S. J Womens Health (Larchmt). 2012 Jun;21(6):674-82. doi: 10.1089/jwh.2011.3153. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency
    S-equol, 10 mg/day, appears to be as effective as soy isoflavones at reducing hot flash frequency and more effective for relieving muscle and joint pain in postmenopausal women.[Article]
  16. Chedraui P, San Miguel G, Schwager G. Gynecol Endocrinol. 2011 May;27(5):307-13. doi: 10.3109/09513590.2010.490614. The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass inde
    In this high risk climacteric population, soy derived isoflavone treatment improved mood as well as vasomotor and general menopausal symptoms.[Abstract]
  17. SAFETY

    META
  18. Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Hum Reprod Update. 2010 Nov-Dec;16(6):745-60. doi: 10.1093/humupd/dmq011 Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials
    Isoflavone intake does not alter breast density in post-menopausal women, but may cause a small increase in breast density in premenopausal women.[Article]
  19. Hui C, Qi X, Qianyong Z, Xiaoli P, Jundong Z, Mantian M. PLoS One. 2013;8(1):e54318. doi: 10.1371/journal.pone.0054318. Flavonoids, flavonoid subclasses and breast cancer risk: a meta-analysis of epidemiologic studies
    The present study suggests the intake of flavonols and flavones, but not other flavonoid subclasses or total flavonoids, is associated with a decreased risk of breast cancer, especially among post-menopausal women.[Abstract]
  20. Atteritano M, Pernice F, Mazzaferro S, Mantuano S, Frisina A, D’Anna R, Cannata ML, Bitto A, Squadrito F, Frisina N, Buemi M. Eur J Pharmacol. 2008 Jul 28;589(1-3):22-6. doi: 10.1016/j.ejphar.2008.04.049. Effects of phytoestrogen genistein on cytogenetic biomarkers in postmenopausal women: 1 year randomized, placebo-controlled study
    Phytoestrogen genistein has been shown in postmenopausal women to be effective in the reduction of cytogenetic biomarkers. The protective effect on genomic damage appears to be a particularly promising tool in reducing the risk of cancer.[Abstract]
  21. Xie Q, Chen ML, Qin Y, Zhang QY, Xu HX, Zhou Y, Mi MT, Zhu JD. Asia Pac J Clin Nutr. 2013;22(1):118-27. doi: 10.6133/apjcn.2013.22.1.16. Isoflavone consumption and risk of breast cancer: a dose-response meta-analysis of observational studies
    Exposure to high isoflavone may be associated with a reduced breast cancer risk in Asian populations, especially in postmenopausal women. However, no significant difference in the studies of Western populations may be due to the low intake of isoflavone levels.[Article]
  22. D’Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, Triolo O, Antico F, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Marini H, Squadrito F. Menopause. 2007 Jul-Aug;14(4):648-55. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study
    The phytoestrogen genistein has been shown to be effective on vasomotor symptoms without an adverse effect on endometrium.[Abstract]
  23. Colacurci N, De Franciscis P, Atlante M, Mancino P, Monti M, Volpini G, Benvenuti C. Gynecol Endocrinol. 2013 Mar;29(3):209-12. doi: 10.3109/09513590.2012.738724. Endometrial, breast and liver safety of soy isoflavones plus Lactobacillus sporogenes in post-menopausal women
    A 12 months treatment with a nutraceutical compound based on isoflavones and Lactobacillus sporogenes at the recommended doses is safe for endometrium, mammary glands and liver function in postmenopausal women.[Abstract]
  24. Qin LQ, Xu JY, Wang PY, Hoshi K. J Nutr Sci Vitaminol (Tokyo). 2006 Dec;52(6):428-36. Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies
    This meta-analysis supported the hypotheses that soyfood intake may be associated with a decreased risk of breast cancer due to the isoflavones.[Article]
  25. RCT
  26. Taylor CK, Levy RM, Elliott JC, Burnett BP. Nutr Rev. 2009 Jul;67(7):398-415. doi: 10.1111/j.1753-4887.2009.00213.x. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies
    In contrast, a recent nested case-control study and meta-analysis of numerous epidemiological studies show an inverse correlation between genistein intake and breast cancer risk.[Abstract]
  27. REVIEW
  28. Messina MJ, Loprinzi CL. J Nutr. 2001 Nov;131(11 Suppl):3095S-108S. Soy for breast cancer survivors: a critical review of the literature
    Consequently, if breast cancer patients enjoy soy products, it seems reasonable for them to continue to use them.[Article]
  29. OSTEOPOROSIS

    META
  30. Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Bone. 2010 Aug;47(2):413-23. doi: 10.1016/j.bone.2010.05.001.
    Soy isoflavone supplements moderately decreased the bone resorption marker DPD, but did not affect bone formation markers BAP and OC in menopausal women.[Abstract]
  31. Ma D, Qin L, Liu B, Wang P. Wei Sheng Yan Jiu. 2009 Sep;38(5):546-51. Inhibition of soy isoflavone intake on bone loss in menopausal women: evaluated by meta-analysis of randomized controlled trials
    It was suggested that the bone loss in menopausal women attenuated by isoflavone intervention could be associated with inhibition of bone resorption and stimulation of bone formation.[Abstract]
  32. Ma DF, Qin LQ, Wang PY, Katoh R. Clin Nutr. 2008 Feb;27(1):57-64. Epub 2007 Dec 11. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials
    Isoflavone intervention significantly attenuates bone loss of the spine in menopausal women. These favorable effects become more significant when more than 90 mg/day of isoflavones are consumed. And soy isoflavone consumption for 6 months can be enough to exert beneficial effects on bone in menopausal women.[Abstract]
  33. Ma DF, Qin LQ, Wang PY, Katoh R. Eur J Clin Nutr. 2008 Feb;62(2):155-61. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials
    Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if <90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.[Article]
  34. Taku K, Melby MK, Takebayashi J, Mizuno S, Ishimi Y, Omori T, Watanabe S. Asia Pac J Clin Nutr. 2010;19(1):33-42. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials
    Soy isoflavone extract supplements increased lumbar spine BMD in menopausal women.[Article]
  35. REVIEW
  36. Scheiber MD, Rebar RW. Menopause. 1999 Fall;6(3):233-41. Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
    The data on naturally occurring isoflavones are very limited but suggest that including them in the diet results in reduction in bone resorption caused by estrogen deficiency.[Abstract]
  37. Park CY, Weaver CM. Nutrients. 2012 Nov 6;4(11):1610-21. doi: 10.3390/nu4111610. Vitamin D interactions with soy isoflavones on bone after menopause: a review
    We discuss a possible synergistic effect of soy isoflavones and vitamin D on bone by affecting osteoblast and osteoclast formation and activity in postmenopausal women.[Article]
  38. OTHER
  39. Benvenuti C, Setnikar I. Arzneimittelforschung. 2011;61(11):605-9. doi: 10.1055/s-0031-1300562. Effect of Lactobacillus sporogenes on oral isoflavones bioavailability: single dose pharmacokinetic study in menopausal women
    A trend is shown for a greater absorption of genistein from a formulation containing lactobacilli.[Abstract]
  40. OBESITY

    META
  41. Zhang YB, Chen WH, Guo JJ, Fu ZH, Yi C, Zhang M, Na XL. Nutrition. 2013 Jan;29(1):8-14. doi: 10.1016/j.nut.2012.03.019. Soy isoflavone supplementation could reduce body weight and improve glucose metabolism in non-Asian postmenopausal women–a meta-analysis
    This meta-analysis showed soy isoflavone supplementation could be beneficial for body weight reduction, glucose, and insulin control in plasma. Large and well-designed studies are recommended to confirm this conclusion.[Abstract]
  42. Anderson JW, Luan J, Høie LH. Adv Ther. 2004 Mar-Apr;21(2):61-75. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity
    SOY may promote more rapid weight loss over the first 8 weeks than other interventions.[Abstract]
  43. RCT
  44. Christie DR, Grant J, Darnell BE, Chapman VR, Gastaldelli A, Sites CK. Am J Obstet Gynecol. 2010 Aug;203(2):153.e1-9. doi: 10.1016/j.ajog.2010.02.058. Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial
    Soy supplementation reduced abdominal fat in obese postmenopausal women. Caucasians primarily lost subcutaneous and total abdominal fat, and African Americans primarily lost total body fat.[Article]
  45. CRP

    META
  46. Dong JY, Wang P, He K, Qin LQ. Menopause. 2011 Nov;18(11):1256-62. doi: 10.1097/gme.0b013e31821bfa24. Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women: meta-analysis of randomized controlled trials
    The present meta-analysis found insufficient evidence that soy isoflavones significantly reduce CRP concentrations in postmenopausal women.[Abstract]
  47. RCT
  48. Zemel MB, Sun X, Sobhani T, Wilson B. Am J Clin Nutr. 2010 Jan;91(1):16-22. doi: 10.3945/ajcn.2009.28468. Effects of dairy compared with soy on oxidative and inflammatory stress in overweight and obese subjects
    An increase in dairy food intake produces significant and substantial suppression of the oxidative and inflammatory stress associated with overweight and obesity.[Article]
  49. CHD

    RCT
  50. Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, Corrado F, D’Anna R, Squadrito G, Adamo EB, Marini R, Romeo A, Cancellieri F, Buemi M, Squadrito F. Menopause. 2005 Mar;12(2):186-92. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women
    Our study suggests that genistein may have a favorable effect on some cardiovascular markers.[Abstract]
  51. SOJA VOEDING

    REVIEW
  52. Liener IE. Crit Rev Food Sci Nutr. 1994;34(1):31-67. Implications of antinutritional components in soybean foods
    Other diverse but ill-defined factors appear to increase the requirements for vitamins A, B12, D, and E.[Abstract]
  53. Gilani GS, Cockell KA, Sepehr E. J AOAC Int. 2005 May-Jun;88(3):967-87. Effects of antinutritional factors on protein digestibility and amino acid availability in foods
    The presence of high levels of dietary trypsin inhibitors from soybeans, kidney beans, or other grain legumes can cause substantial reductions in protein and amino acid digestibilities (up to 50%) in rats and pigs.[Abstract]
  54. Lönnerdal B, Cederblad A, Davidsson L, Sandström B. Am J Clin Nutr. 1984 Nov;40(5):1064-70. The effect of individual components of soy formula and cows’ milk formula on zinc bioavailability
    Phytate was found to have a strong inhibitory effect on zinc absorption; addition of phytate to cows’ milk formula (yielding a phytate concentration similar to that of soy formula) resulted in a decrease in zinc absorption from 31 to 16% similar to the absorption for soy formula (14%). .[Article]
  55. Doerge DR, Sheehan DM. Environ Health Perspect. 2002 Jun;110 Suppl 3:349-53. Goitrogenic and estrogenic activity of soy isoflavones
    We then focus on evidence from animal and human studies suggesting a link between soy consumption and goiter, an activity independent of estrogenicity. Iodine deficiency greatly increases soy antithyroid effects, whereas iodine supplementation is protective. Thus, soy effects on the thyroid involve the critical relationship between iodine status and thyroid function.[Article]

Voedingsadvies voor de menopauze

    Vermindering risico op osteoporose

    REVIEW
  1. ESHRE Capri Workshop Group. Hum Reprod Update. 2010 Nov-Dec;16(6):761-73. doi: 10.1093/humupd/dmq008. Bone fractures after menopause
    Ageing reduces bone strength in post-menopausal women because estrogen deficiency causes accelerated bone resorption..[Article]
  2. Soja vermindert risico osteoporose

    META
  3. Bolaños R1, Francia J. Menopause. 2010 Nov-Dec;17(6):1201-5. doi: 10.1097/gme.0b013e3181df48f0. Isoflavones versus hormone therapy for reduction of vertebral fracture risk: indirect comparison
    According to this indirect comparison, there is no statistically significant difference between HT or isoflavones in the reduction of vertebral fracture risk due to osteoporosis, and both interventions seem to be similar for this outcome.[Abstract]
  4. REVIEW
  5. Scheiber MD1, Rebar RW. Menopause. 1999 Fall;6(3):233-41. Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
    The data on naturally occurring isoflavones are very limited but suggest that including them in the diet results in reduction in bone resorption caused by estrogen deficiency.[Abstract]
  6. META
  7. Taku K1, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Bone. 2010 Aug;47(2):413-23. doi: 10.1016/j.bone.2010.05.001. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials
    Soy isoflavone supplements moderately decreased the bone resorption marker DPD.[Abstract]
  8. Roken

    META
  9. Ward KD1, Klesges RC. Calcif Tissue Int. 2001 May;68(5):259-70. A meta-analysis of the effects of cigarette smoking on bone mineral density
    Based on these data, it is estimated that smoking increases the lifetime risk of developing a vertebral fracture by 13% in women and 32% in men. At the hip, smoking is estimated to increase lifetime fracture risk by 31% in women and 40% in men. It appears that smoking has an independent, dose-dependent effect on bone loss, which increases fracture risk, and may be partially reversed by smoking cessation. Given the public health implications of smoking on bone health, it is important that this information be incorporated into smoking prevention and cessation efforts.[Abstract]
  10. META
  11. Law MR1, Hackshaw AK. BMJ. 1997 Oct 4;315(7112):841-6. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect
    Hip fracture in old age is a major adverse effect of smoking after the menopause.[Article]
  12. REVIEW
  13. ESHRE Capri Workshop Group1. Hum Reprod Update. 2011 Sep-Oct;17(5):706-17. doi: 10.1093/humupd/dmr020.
    Osteoarthritis frequency increases after 50 years of age and risk is elevated 3-fold by obesity, while risk of osteoporosis can be minimized by smoking cessation, adequate vitamin D intake and regular weight-bearing exercise. Lifestyle changes around the time of the perimenopause can reduce the likelihood and severity of heart disease and chronic illness in later years and the cost of care of elderly women.[Article]
  14. Vitamine D

    META
  15. Jackson C1, Gaugris S, Sen SS, Hosking D. QJM. 2007 Apr;100(4):185-92. Epub 2007 Feb 17. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis
    There is a trend towards a reduction in the risk of fall among patients treated with vitamin D(3) alone compared with placebo, suggesting that vitamin D(3) should be an integral part of effective osteoporosis management.[Article]
  16. META
  17. Avenell A1, Mak JC, O’Connell D. Cochrane Database Syst Rev. 2014 Apr 14;4:CD000227. doi: 10.1002/14651858.CD000227.pub4. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men
    Vitamin D alone is unlikely to prevent fractures in the doses and formulations tested so far in older people. Supplements of vitamin D and calcium may prevent hip or any type of fracture.[Article]
  18. Verminder risico op borstkanker

    META
  19. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet Oncol. 2012 Nov;13(11):1141-51. doi: 10.1016/S1470-2045(12)70425-4. E Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
    Breast cancer risk increased by a factor of 1·050 (95% CI 1·044-1·057; p<0·0001) for every year younger at menarche, and independently by a smaller amount (1·029, 1·025-1·032; p<0·0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1·43, 1·33-1·52, p<0·001).[Article]
  20. Borstvoeding

    REVIEW
  21. Turck D; Comité de nutrition de la Société française de pédiatrie. Arch Pediatr. 2005 Dec;12 Suppl 3:S145-65. Breast feeding: health benefits for child and mother
    Breastfeeding is also associated with a decreased risk of breast and ovarian cancer in the premenopausal period, and of hip fractures and osteoporosis in the postmenopausal period.[Abstract]
  22. META
  23. Zhou Y1, Chen J, Li Q, Huang W, Lan H, Jiang H Breastfeed Med. 2015 Apr;10(3):175-82. doi: 10.1089/bfm.2014.0141. Association between breastfeeding and breast cancer risk: evidence from a meta-analysis
    Findings from this meta-analysis suggest that breastfeeding, particularly a longer duration of breastfeeding, was inversely associated with risk of breast cancer.[Abstract]
  24. META
  25. Anothaisintawee T1, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, Hirunpat S, Woodtichartpreecha P, Boonlikit S, Teerawattananon Y, Thakkinstian A. Asia Pac J Public Health. 2013 Sep;25(5):368-87. doi: 10.1177/1010539513488795. Risk factors of breast cancer: a systematic review and meta-analysis
    Our study suggests that OC, HRT, and DM might increase risks, whereas breastfeeding might lower risks of breast cancer.[Abstract]
  26. Overgewicht

    META
  27. Xia X1, Chen W2, Li J2, Chen X2, Rui R2, Liu C2, Sun Y2, Liu L3, Gong J2, Yuan P4. Sci Rep. 2014 Dec 15;4:7480. doi: 10.1038/srep07480. Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies
    In conclusion, the results of this meta-analysis highlighted that obesity contributed to increased BC risk in a nonlinear dose-response manner in postmenopausal women, and it is important to realize that body weight control may be a crucial process to reduce BC susceptibility.[Article]
  28. META
  29. Chan DS1, Vieira AR2, Aune D3, Bandera EV4, Greenwood DC5, McTiernan A6, Navarro Rosenblatt D2, Thune I7, Vieira R8, Norat T2. Ann Oncol. 2014 Oct;25(10):1901-14. doi: 10.1093/annonc/mdu042. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
    Obesity is associated with poorer overall and breast cancer survival in pre- and post-menopausal breast cancer, regardless of when BMI is ascertained. Being overweight is also related to a higher risk of mortality.[Article]
  30. META
  31. Protani M1, Coory M, Martin JH. Breast Cancer Res Treat. 2010 Oct;123(3):627-35. doi: 10.1007/s10549-010-0990-0 Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
    Obesity is a risk factor for the development of new cases of breast cancer and also affects survival in women who have already been diagnosed with breast cancer.[Abstract]
  32. REVIEW
  33. Linos E1, Holmes MD, Willett WC. Curr Oncol Rep. 2007 Jan;9(1):31-41. Diet and breast cancer
    Excess weight and weight gain in adult life are related to higher risk of postmenopausal breast cancer, and weight loss after menopause is associated with substantially reduced risk.[Abstract]
  34. Metabole syndroom

    SURVEY
  35. RIVM Nederland de Maat Genomen, 2009- 2010
    Men spreekt van de aanwezigheid van metabool syndroom, als drie of meer van de volgende risicofactoren aanwezig zijn: abdominale obesitas (middelomtrek mannen ? 102 cm, vrouwen ? 88 cm); matig verhoogde bloeddruk (systole ? 130 mmHg en/of diastole ? 85 mmHg en/of bloeddrukverlagende medicatie); laag HDL (mannen < 1,03 mmol/l, vrouwen < 1,30 mmol/l en/of medicatie voor cholesterol); verhoogd glucose (nuchter ? 5,6 mmol/l, niet-nuchter ? 7,8 mmol/l en/of medicatie voor diabetes); verhoogde triglyceriden (? 1,7 mmol/l).[Article]
  36. REVIEW
  37. Lobo RA. Maturitas. 2008 May 20;60(1):10-8. doi: 10.1016/j.maturitas.2008.02.008. Metabolic syndrome after menopause and the role of hormones
    MBS may occur in 40% of PM women and is largely determined by overweight status and obesity.[Abstract]
  38. META
  39. Esposito K1, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Giugliano D. Menopause. 2013 Dec;20(12):1301-9. doi: 10.1097/GME.0b013e31828ce95d. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis
    MS is associated with a moderately increased risk of PBC. No single component explains the risk conveyed by the full syndrome.[Abstract]
  40. META
  41. Esposito K1, Chiodini P, Colao A, Lenzi A, Giugliano D. Diabetes Care. 2012 Nov;35(11):2402-11. doi: 10.2337/dc12-0336. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis
    Metabolic syndrome is associated with increased risk of common cancers; for some cancers, the risk differs betweens sexes, populations, and definitions of metabolic syndrome.[Article]
  42. Diabetes

    META
  43. Boyle P1, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Boniol M, Zheng T, Zhang Y, Pasterk M, Smans M, Curado MP, Mullie P, Gandini S, Bota M, Bolli GB, Rosenstock J, Autier P. Br J Cancer. 2012 Oct 23;107(9):1608-17. doi: 10.1038/bjc.2012.414. Diabetes and breast cancer risk: a meta-analysi
    The risk of breast cancer in women with type 2 diabetes is increased by 27%, a figure that decreased to 16% after adjustment for BMI. No increased risk was seen for women at pre-menopausal ages or with type 1 diabetes.[Article]
  44. META
  45. Liao S1, Li J, Wei W, Wang L, Zhang Y, Li J, Wang C, Sun S. Asian Pac J Cancer Prev. 2011;12(4):1061-5. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature
    This meta-analysis indicated that diabetes can be considered as a risk factor for breast cancer. In addition, menstruation status as well as geographical distribution can affect the relationship.[Abstract]
  46. META
  47. Larsson SC1, Mantzoros CS, Wolk A. Int J Cancer. 2007 Aug 15;121(4):856-62 Diabetes mellitus and risk of breast cancer: a meta-analysis
    Meta-analysis of 5 cohort studies on diabetes and mortality from breast cancer yielded a summary RR of 1.24 (95% CI, 0.95-1.62) for women with (versus without) diabetes. Findings from this meta-analysis indicate that diabetes is associated with an increased risk of breast cancer.[Article]
  48. META
  49. Buchwald H1, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. JAMA. 2004 Oct 13;292(14):1724-37. Bariatric surgery: a systematic review and meta-analysis
    Diabetes was completely resolved in 76.8% of patients and resolved or improved in 86.0%. Hyperlipidemia improved in 70% or more of patients. Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients.[Abstract]
  50. REVIEW
  51. Taylor R1. Diabetes Care. 2013 Apr;36(4):1047-55. doi: 10.2337/dc12-1805. Type 2 diabetes: etiology and reversibility
    Reversal of type 2 diabetes to normal metabolic control by either bariatric surgery or hypocaloric diet allows for the time sequence of underlying pathophysiologic mechanisms to be observed. [Article]
  52. Metformine

    META
  53. Col NF1, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Breast Cancer Res Treat. 2012 Oct;135(3):639-46. doi: 10.1007/s10549-012-2170-x Metformin and breast cancer risk: a meta-analysis and critical literature review
    Our analyses support a protective effect of metformin on breast cancer risk among postmenopausal women with diabetes. Clinical trials are needed for definitive determination of the role of metformin in breast cancer risk reductio.[Abstract]
  54. META
  55. Gandini S1, Puntoni M2, Heckman-Stoddard BM3, Dunn BK4, Ford L5, DeCensi A6, Szabo E7. Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. doi: 10.1158/1940-6207.CAPR-13-0424. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders
    We included estimates from 47 independent studies and 65,540 cancer cases in patients with diabetes. Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52-0.90], although between-study heterogeneity was considerable (I(2) = 88%).[Abstract]
  56. META
  57. Decensi A1, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. doi: 10.1158/1940-6207.CAPR-10-0157. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis
    Metformin is associated with a decreased risk of cancer incidence compared with other treatments among diabetic patients.[Article]
  58. Alcohol

    META
  59. Bagnardi V1, Rota M2, Botteri E3, Tramacere I4, Islami F5, Fedirko V6, Scotti L7, Jenab M8, Turati F9, Pasquali E3, Pelucchi C10, Galeone C10, Bellocco R11, Negri E10, Corrao G7, Boffetta P12, La Vecchia C13 Br J Cancer. 2015 Feb 3;112(3):580-93. doi: 10.1038/bjc.2014.579. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis
    Alcohol increases risk of cancer of oral cavity and pharynx, oesophagus, colorectum, liver, larynx and female breast.[Article]
  60. META
  61. Cummings SR1, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K. J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. doi: 10.1093/jnci/djp018. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk
    Most studies found that exercise, weight reduction, low-fat diet, and reduced alcohol intake were associated with a decreased risk of breast cancer.[Article]
  62. META
  63. Key J1, Hodgson S, Omar RZ, Jensen TK, Thompson SG, Boobis AR, Davies DS, Elliott P. Cancer Causes Control. 2006 Aug;17(6):759-70. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues
    Taking account of shortcomings in the study base and methodological concerns, we confirm the alcohol-breast cancer association.[Abstract]
  64. META
  65. Smith-Warner SA1, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR, Miller AB, Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ. JAMA. 1998 Feb 18;279(7):535-40. Alcohol and breast cancer in women: a pooled analysis of cohort studies
    Alcohol consumption is associated with a linear increase in breast cancer incidence in women over the range of consumption reported by most women. Among women who consume alcohol regularly, reducing alcohol consumption is a potential means to reduce breast cancer risk.[Abstract]
  66. REVIEW
  67. Linos E1, Willett WC. J Natl Compr Canc Netw. 2007 Sep;5(8):711-718 Diet and breast cancer risk reduction
    Additionally, alcohol increases the risk for breast cancer even at moderate levels of intake, and women who drink alcohol also should take sufficient folate, which can mitigate this excess risk.[Abstract]
  68. Vitamine D

    META
  69. Gissel T1, Rejnmark L, Mosekilde L, Vestergaard P. J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):195-9. doi: 10.1016/j.jsbmb.2008.06.002. Intake of vitamin D and risk of breast cancer–a meta-analysis
    In conclusion there may be a trend towards fewer cases of breast cancer with higher intakes of vitamin D.[Abstract]
  70. REVIEW
  71. Giammanco M1, Di Majo D, La Guardia M, Aiello S, Crescimannno M, Flandina C, Tumminello FM, Leto G. Pharm Biol. 2015;53(10):1399-434. doi: 10.3109/13880209.2014.988274. Vitamin D in cancer chemoprevention
    Experimental and clinical observations suggest that Vit D and its analogues may be effective in preventing the malignant transformation and/or the progression of various types of human tumors including breast cancer, prostate cancer, colorectal cancer, and some hematological malignances. These findings suggest the possibility of the clinical use of these molecules as novel potential chemopreventive and anticancer agents.[Abstract]
  72. META
  73. Chen P1, Hu P, Xie D, Qin Y, Wang F, Wang H. Breast Cancer Res Treat. 2010 Jun;121(2):469-77. doi: 10.1007/s10549-009-0593-9. Meta-analysis of vitamin D, calcium and the prevention of breast cancer
    These results provide strong evidence that vitamin D and calcium have a chemopreventive effect against breast cancer.[Abstract]
  74. META
  75. Chen P1, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, Zhu J, Ou Z, Wang H. PLoS One. 2013;8(1):e49312. doi: 10.1371/journal.pone.0049312. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studie
    These results suggest that vitamin D may have a chemo-preventive effect against breast cancer.[Article]
  76. META
  77. Mohr SB1, Gorham ED, Kim J, Hofflich H, Garland CF. Anticancer Res. 2014 Mar;34(3):1163-6. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer
    High serum 25(OH)D was associated with lower mortality from breast cancer.[Article]
  78. META
  79. Kim Y1, Je Y1. Br J Cancer. 2014 May 27;110(11):2772-84. doi: 10.1038/bjc.2014.175. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis
    Our findings suggest that high vitamin D status is weakly associated with low breast cancer risk but strongly associated with better breast cancer survival..[Article]
  80. META
  81. Li M1, Chen P, Li J, Chu R, Xie D, Wang H. J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36. doi: 10.1210/jc.2013-4320. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis
    The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes.[Article]
  82. Soja vermindert risico borstkanker

    META
  83. Zhong X1, Zhang C. Wei Sheng Yan Jiu. 2012 Jul;41(4):670-6. Soy food intake and breast cancer risk: a meta-analysis
    According to the meta-analysis of studies conducted in Asian countries, soy food intake is inversely associated with the risk of breast cancer among Asian women, especially based on the results of meta-analysis of case-control studies.[Abstract]
  84. META
  85. Qin LQ1, Xu JY, Wang PY, Hoshi K. J Nutr Sci Vitaminol (Tokyo). 2006 Dec;52(6):428-36. Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies
    This meta-analysis supported the hypotheses that soyfood intake may be associated with a decreased risk of breast cancer due to the isoflavones.[Abstract]
  86. META
  87. Trock BJ1, Hilakivi-Clarke L, Clarke R. J Natl Cancer Inst. 2006 Apr 5;98(7):459-71. Meta-analysis of soy intake and breast cancer risk
    Soy intake may be associated with a small reduction in breast cancer risk.[Article]
  88. META
  89. Badger TM1, Ronis MJ, Simmen RC, Simmen FA. J Am Coll Nutr. 2005 Apr;24(2):146S-149S. Soy protein isolate and protection against cancer
    SPI may protect against cancer via multiple mechanisms, including: 1) increased mammary gland differentiation, 2) decreased activation of procarcinogens to carcinogens and 3) regulation of genes in signal transduction pathways underlying tumor initiation, promotion and/or progressio.[Abstract]
  90. META
  91. Chi F1, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Asian Pac J Cancer Prev. 2013;14(4):2407-12. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studie
    Our meta- analysis showed that soy food intake might be associated with better survival, especially for ER negative, ER+/ PR+, and postmenopausal patients.[Abstract]
  92. Soja verhoogd niet risico op borstkanker

    META
  93. Hooper L1, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Hum Reprod Update. 2010 Nov-Dec;16(6):745-60. doi: 10.1093/humupd/dmq011. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials
    soflavone intake does not alter breast density in post-menopausal women, but may cause a small increase in breast density in premenopausal women. Larger, long-term trials are required to determine if these small effects are clinically relevant.[Article]
  94. RCT
  95. Atteritano M1, Pernice F, Mazzaferro S, Mantuano S, Frisina A, D’Anna R, Cannata ML, Bitto A, Squadrito F, Frisina N, Buemi M. Eur J Pharmacol. 2008 Jul 28;589(1-3):22-6. doi: 10.1016/j.ejphar.2008.04.049. Effects of phytoestrogen genistein on cytogenetic biomarkers in postmenopausal women: 1 year randomized, placebo-controlled study
    Phytoestrogen genistein has been shown in postmenopausal women to be effective in the reduction of cytogenetic biomarkers. The protective effect on genomic damage appears to be a particularly promising tool in reducing the risk of cancer.[Abstract]
  96. Extra beweging bij osteoporose

    META
  97. Zhao R1, Zhao M, Xu Z. Osteoporos Int. 2015 May;26(5):1605-18. doi: 10.1007/s00198-015-3034-0. The effects of differing resistance training modes on the preservation of bone mineral density in postmenopausal women: a meta-analysis
    Combined resistance exercise protocols appear effective in preserving femoral neck and lumbar spine BMD in postmenopausal women, whereas resistance-alone protocols only produced a nonsignificant positive effect..[Abstract]
  98. META
  99. Zhao R1, Zhao M, Zhang L. Sports Med. 2014 Oct;44(10):1393-402. doi: 10.1007/s40279-014-0220-8 Efficiency of jumping exercise in improving bone mineral density among premenopausal women: a meta-analysis
    Based on meta-analysis of existing studies, the sensitivity of skeletal response to jumping exercise in premenopausal women is significant and site-specific, with significant benefit from high-impact exercise noted, especially at the hip.[Abstract]
  100. META
  101. Babatunde OO1, Forsyth JJ, Gidlow CJ. Osteoporos Int. 2012 Jan;23(1):109-19. doi: 10.1007/s00198-011-1801-0. A meta-analysis of brief high-impact exercises for enhancing bone health in premenopausal women
    Based on the meta-analysis, brief high-impact exercise improves BMD at the hip but not at the lumbar spine. Effectiveness of this form of exercise as a lifestyle physical activity for prevention of osteoporosis should be explored in larger populations.[Abstract]
  102. META
  103. Martyn-St James M1, Carroll S. J Bone Miner Metab. 2010 May;28(3):251-67. doi: 10.1007/s00774-009-0139-6. Effects of different impact exercise modalities on bone mineral density in premenopausal women: a meta-analysis
    Exercise programmes that combine odd- or high-impact activity with high-magnitude resistance training appear effective in augmenting BMD in premenopausal women at the hip and spine.[Article]
  104. META
  105. Howe TE1, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD000333. doi: 10.1002/14651858.CD000333.pub2. Exercise for preventing and treating osteoporosis in postmenopausal women
    Our results suggest a relatively small statistically significant, but possibly important, effect of exercise on bone density compared with control groups. Exercise has the potential to be a safe and effective way to avert bone loss in postmenopausal women.[Abstract]
  106. META
  107. Martyn-St James M1, Carroll S. Br J Sports Med. 2009 Dec;43(12):898-908. doi: 10.1136/bjsm.2008.052704. A meta-analysis of impact exercise on postmenopausal bone loss: the case for mixed loading exercise programmes
    Mixed loading exercise programmes combining jogging with other low-impact loading activity and programmes mixing impact activity with high-magnitude exercise as resistance training appear effective in reducing postmenopausal bone loss at the hip and spine.[Article]
  108. Bonaiuti D1, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, Wells G, Tugwell P, Cranney A. Cochrane Database Syst Rev. 2002;(3):CD000333. Exercise for preventing and treating osteoporosis in postmenopausal women
    Aerobics, weight bearing and resistance exercises are all effective in increasing the BMD of the spine in postmenopausal women. Walking is also effective on the hip.[Abstract]
  109. META
  110. Ho-Pham LT1, Nguyen UD, Nguyen TV. J Clin Endocrinol Metab. 2014 Jan;99(1):30-8. doi: 10.1210/jc.2013-3190. Association between lean mass, fat mass, and bone mineral density: a meta-analysis
    LM exerts a greater effect on BMD than FM in men and women combined. This finding underlines the concept that physical activity is an important component in the prevention of bone loss and osteoporosis in the population.[Abstract]
  111. OTHER
  112. Tucker LA, Strong JE, LeCheminant JD, Bailey BW. Am J Health Promot. 2015 Jan-Feb;29(3):158-64. doi: 10.4278/ajhp.130430-QUAN-200. Effect of two jumping programs on hip bone mineral density in premenopausal women: a randomized controlled trial
    After 16 weeks of high-impact jump training, hip BMD can be improved in premenopausal women by jumping 10 or 20 times, twice daily, with 30 seconds of rest between each jump, compared with controls.[Abstract]
  113. REVIEW
  114. Bailey CA1, Brooke-Wavell K. Proc Nutr Soc. 2008 Feb;67(1):9-18. doi: 10.1017/S0029665108005971. Exercise for optimising peak bone mass in women
    Unilateral high-impact exercise may therefore improve bone strength of the trained limb and provide a useful model for comparing exercise prescriptions to help define the most efficient and effective exercise recommendations for the bone health of premenopausal women..[Article]
  115. Probiotica

    CLINICAL
  116. Xiao S1, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, Li M, Sun L, Xue Z, Wang J, Feng J, Yan F, Zhao N, Liu J, Long W, Zhao L. FEMS Microbiol Ecol. 2014 Feb;87(2):357-67. doi: 10.1111/1574-6941.12228. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome
    These results suggest that modulation of the gut microbiota via dietary intervention may enhance the intestinal barrier integrity, reduce circulating antigen load, and ultimately ameliorate the inflammation and metabolic phenotypes.[Article]
  117. RCT
  118. Asemi Z1, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Ann Nutr Metab. 2013;63(1-2):1-9. doi: 10.1159/000349922. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes
    In conclusion, multispecies probiotic supplementation, compared with placebo, for 8 weeks in diabetic patients prevented a rise in FPG and resulted in a decrease in serum hs-CRP and an increase in plasma total GSH.[Abstract]
  119. RCT
  120. Alokail MS1, Sabico S, Al-Saleh Y, Al-Daghri NM, Alkharfy KM, Vanhoutte PM, McTernan PG. Trials. 2013 Jul 4;14:195. doi: 10.1186/1745-6215-14-195. Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial
    It is expected that the probiotic product will induce beneficial changes in gut microbiota, reduce the systemic inflammatory state through altering systemic endotoxin levels and, as such, reduce the systemic inflammatory response observed in T2DM subjects.[Article]
  121. RCT
  122. Asemi Z1, Khorrami-Rad A2, Alizadeh SA3, Shakeri H1, Esmaillzadeh A4. Clin Nutr. 2014 Apr;33(2):198-203. doi: 10.1016/j.clnu.2013.05.015. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial
    In conclusion, consumption of a synbiotic food for 6 weeks among diabetic patients had significant effects on serum insulin, hs-CRP, uric acid and plasma total GSH levels.[Abstract]
  123. RCT
  124. Groeger D1, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Gut Microbes. 2013 Jul-Aug;4(4):325-39. doi: 10.4161/gmic.25487. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut
    In conclusion, these data show that the immunomodulatory effects of the microbiota in humans are not limited to the mucosal immune system but extend to the systemic immune system.[Article]
  125. REVIEW
  126. Festi D1, Schiumerini R1, Eusebi LH1, Marasco G1, Taddia M1, Colecchia A1. World J Gastroenterol. 2014 Nov 21;20(43):16079-94. doi: 10.3748/wjg.v20.i43.16079. Gut microbiota and metabolic syndrome
    Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low grade inflammation and improve gut barrier integrity, thus, ameliorating metabolic balance and promoting weight loss. However, further evidence is needed to better understand their clinical impact and therapeutic use.[Article]
  127. REVIEW
  128. Fallucca F1, Porrata C, Fallucca S, Pianesi M. Diabetes Metab Res Rev. 2014 Mar;30 Suppl 1:48-54. doi: 10.1002/dmrr.2518. nfluence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet
    Results suggested that it could induce a significant improvement in fasting blood glucose, plasma lipid fractions, plasma insulin and homeostasis. It is therefore possible that a diet rich in prebiotics and probiotics can play a role in T2DM management, probably due to positive intestinal microbiota modulation.[Abstract]
  129. Overgewicht

    META
  130. Zhang YB1, Chen WH, Guo JJ, Fu ZH, Yi C, Zhang M, Na XL. Nutrition. 2013 Jan;29(1):8-14. doi: 10.1016/j.nut.2012.03.019. Soy isoflavone supplementation could reduce body weight and improve glucose metabolism in non-Asian postmenopausal women–a meta-analysis
    This meta-analysis showed soy isoflavone supplementation could be beneficial for body weight reduction, glucose, and insulin control in plasma.[Abstract]
  131. META
  132. Wu J1, Dong J, Jiang X, Qin L. Wei Sheng Yan Jiu. 2013 Mar;42(2):185-9. Effects of soy protein supplement on overweight and obese population: meta-analysis of randomized controlled trials
    Soy protein supplementation significantly decreased body weight, fat mass and waist circumference in overweight and obese population.[Abstract]
  133. META
  134. Anderson JW1, Luan J, Høie LH. Adv Ther. 2004 Mar-Apr;21(2):61-75. Structured weight-loss programs: meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity
    SOY may promote more rapid weight loss over the first 8 weeks than other interventions..[Abstract]
  135. Groene thee

    META
  136. Huang J1, Wang Y1, Xie Z1, Zhou Y1, Zhang Y1, Wan X1. Eur J Clin Nutr. 2014 Oct;68(10):1075-87. doi: 10.1038/ejcn.2014.143. The anti-obesity effects of green tea in human intervention and basic molecular studies
    Moreover, data from laboratory studies have shown that green tea has important roles in fat metabolism by reducing food intake, interrupting lipid emulsification and absorption, suppressing adipogenesis and lipid synthesis and increasing energy expenditure via thermogenesis, fat oxidation and fecal lipid excretion. However, the exact molecular mechanisms remain elusive.[Abstract]
  137. META
  138. Hursel R1, Viechtbauer W, Westerterp-Plantenga MS. Int J Obes (Lond). 2009 Sep;33(9):956-61. doi: 10.1038/ijo.2009.135. Epub 2009 Jul 14. The effects of green tea on weight loss and weight maintenance: a meta-analysis
    Catechins or an epigallocatechin gallate (EGCG)-caffeine mixture have a small positive effect on WL and WM..[Article]
  139. META
  140. Tang J1, Zheng JS1, Fang L2, Jin Y2, Cai W1, Li D1 Br J Nutr. 2015 Sep 14;114(5):673-83. doi: 10.1017/S0007114515002329. Tea consumption and mortality of all cancers, CVD and all causes: a meta-analysis of eighteen prospective cohort studies
    The dose-response analysis indicated that one cup per d increment of green tea consumption was associated with 5 % lower risk of CVD mortality and with 4 % lower risk of all-cause mortality. Green tea consumption was significantly inversely associated with CVD and all-cause mortality, whereas black tea consumption was significantly inversely associated with all cancer and all-cause mortality.[Abstract]
  141. Vitamine D voor preventie maar niet voor genezing

    META
  142. Ju SY1, Jeong HS, Kim do H. J Clin Endocrinol Metab. 2014 Mar;99(3):1053-63. doi: 10.1210/jc.2013-3577. Blood vitamin D status and metabolic syndrome in the general adult population: a dose-response meta-analysis
    Blood vitamin D levels were associated with a risk of metabolic syndrome in cross-sectional studies but not in longitudinal studies. .[Article]
  143. META
  144. Afzal S1, Bojesen SE, Nordestgaard BG. Clin Chem. 2013 Feb;59(2):381-91. doi: 10.1373/clinchem.2012.193003. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis
    We observed an association of low plasma 25(OH)D with increased risk of type 2 diabetes. This finding was substantiated in a metaanalysis.[Article]
  145. META
  146. Khan H1, Kunutsor S, Franco OH, Chowdhury R. Proc Nutr Soc. 2013 Feb;72(1):89-97. doi: 10.1017/S0029665112002765. Vitamin D, type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies
    In conclusion, vitamin D status at baseline in apparently healthy adults is inversely associated with future risks of T2D and MetS. Interventions aimed at maintaining adequate levels of vitamin D in addition to preventing deficiency may be a useful preventive measure for metabolic diseases.[Article]
  147. META
  148. Parker J1, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH. Maturitas. 2010 Mar;65(3):225-36. doi: 10.1016/j.maturitas.2009.12.013. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis
    High levels of vitamin D among middle-age and elderly populations are associated with a substantial decrease in cardiovascular disease, type 2 diabetes and metabolic syndrome. If the relationship proves to be causal, interventions targeting vitamin D deficiency in adult populations could potentially slow the current epidemics of cardiometabolic disorders.[Abstract]
  149. META
  150. Mitri J1, Pittas AG2. Endocrinol Metab Clin North Am. 2014 Mar;43(1):205-32. doi: 10.1016/j.ecl.2013.09.010. Vitamin D and diabetes
    There has been increasing evidence that vitamin D may have a role in modifying risk of diabetes. Vitamin D has both direct and indirect effects on various mechanisms related to the pathophysiology of type 2 diabetes, including pancreatic beta cell dysfunction, impaired insulin action and systemic inflammation.[Article]
  151. META
  152. Forouhi NG1, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, Wareham NJ. Diabetologia. 2012 Aug;55(8):2173-82. doi: 10.1007/s00125-012-2544-y. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies
    These findings demonstrate an inverse association between circulating 25(OH)D and incident type 2 diabetes.[Article]
  153. META
  154. George PS1, Pearson ER, Witham MD. Diabet Med. 2012 Aug;29(8):e142-50. doi: 10.1111/j.1464-5491.2012.03672.x. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis
    There is currently insufficient evidence of beneficial effect to recommend vitamin D supplementation as a means of improving glycaemia or insulin resistance in patients with diabetes, normal fasting glucose or impaired glucose tolerance.[Article]
  155. Intermitted fasting

    OTHER
  156. Wikipedia Leptine
    Dit hormoon werd daarom oorspronkelijk gezien als een “hongerhormoon”. Hoe meer leptine er in het bloed circuleert, hoe meer verzadigd men zich voelt. Het hormoon wordt hoofdzakelijk afgescheiden door wit vetweefsel.[Article]
  157. REVIEW
  158. Morris DL1, Rui L. Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1247-59. doi: 10.1152/ajpendo.00274.2009. Recent advances in understanding leptin signaling and leptin resistance
    he brain controls energy homeostasis and body weight by integrating various metabolic signals. Leptin, an adipose-derived hormone, conveys critical information about peripheral energy storage and availability to the brain.[Article]
  159. REVIEW
  160. Banks WA1. Curr Pharm Des. 2008;14(16):1606-14. The blood-brain barrier as a cause of obesity
    Hallmarks of starvation include decreased secretion of leptin by adipose tissue and hypertriglyceridemia. Triglycerides inhibit the transport of leptin across the BBB, thus attenuating the leptin signal across the BBB and providing a mechanism for peripheral leptin resistance. Triglycerides are elevated in both starvation and obesity.[Abstract]
  161. REVIEW
  162. Fietta P1 Minerva Med. 2005 Apr;96(2):65-75. Focus on leptin, a pleiotropic hormone
    Leptin, released by the adipocytes into the bloodstream in positive correlation to the fat mass, plays a key role in the body weight control. Indeed, it suppresses the appetite and increases the metabolic rate, primarily acting through central pathways. Conversely, during starvation leptinemia rapidly falls, leading to a reduction of the energy expenditure and allowing a longer survival.[Abstract]
  163. REVIEW
  164. Achten J1, Jeukendrup AE. Nutrition. 2004 Jul-Aug;20(7-8):716-27. Optimizing fat oxidation through exercise and diet
    Ingestion of carbohydrate in the hours before or on commencement of exercise reduces the rate of fat oxidation significantly compared with fasted conditions, whereas fasting longer than 6 h optimizes fat oxidation..[Abstract]
  165. REVIEW
  166. Martin WH 3rd1. Exerc Sport Sci Rev. 1996;24:203-31. Effects of acute and chronic exercise on fat metabolism
    Fatty acids are an important source of energy for skeletal muscle contraction, particularly during exercise of mild-moderate intensity, prolonged duration, and in the fasting state. Plasma FFA transported from remote adipose tissue stores and triglycerides contained within skeletal muscle fibers are the major sources of these fatty acids.[Abstract]
  167. META
  168. Halton TL1, Hu FB. J Am Coll Nutr. 2004 Oct;23(5):373-85 The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review
    There is convincing evidence that a higher protein intake increases thermogenesis and satiety compared to diets of lower protein content.[Article]
  169. Hart- en vaatziekten

    Cholesterol veroorzaakt geen hart en vaatziekten

    REVIEW
  170. Fernandez ML1. Curr Opin Clin Nutr Metab Care. 2012 Mar;15(2):117-21. doi: 10.1097/MCO.0b013e32834d2259. Rethinking dietary cholesterol
    The European countries, Australia, Canada, New Zealand, Korea and India among others do not have an upper limit for cholesterol intake in their dietary guidelines. Further, existing epidemiological data have clearly demonstrated that dietary cholesterol is not correlated with increased risk for CHD. Although numerous clinical studies have shown that dietary cholesterol challenges may increase plasma LDL cholesterol in certain individuals, who are more sensitive to dietary cholesterol (about one-quarter of the population), HDL cholesterol also rises resulting in the maintenance of the LDL/HDL cholesterol ratio, a key marker of CHD risk. The lines of evidence coming from current epidemiological studies and from clinical interventions utilizing different types of cholesterol challenges support the notion that the recommendations limiting dietary cholesterol should be reconsidered.[Abstract]
  171. REVIEW
  172. Fernandez ML1, Calle M. Curr Atheroscler Rep. 2010 Nov;12(6):377-83. doi: 10.1007/s11883-010-0130-7. Revisiting dietary cholesterol recommendations: does the evidence support a limit of 300 mg/d?
    The perceived association between dietary cholesterol (DC) and risk for coronary heart disease (CHD) has resulted in recommendations of no more than 300 mg/d for healthy persons in the United States. These dietary recommendations proposed in the 1960s had little scientific evidence other than the known association between saturated fat and cholesterol and animal studies where cholesterol was fed in amounts far exceeding normal intakes.[Abstract]
  173. REVIEW
  174. McNamara DJ1. Proc Nutr Soc. 2014 May;73(2):161-6. doi: 10.1017/S0029665113003844. Dietary cholesterol, heart disease risk and cognitive dissonance
    In the 1960s, the thesis that dietary cholesterol contributes to blood cholesterol and heart disease risk was a rational conclusion based on the available science at that time. Fifty years later the research evidence no longer supports this hypothesis yet changing the dietary recommendation to limit dietary cholesterol has been a slow and at times contentious process. In contrast, health promotion groups in some countries appear to suffer from cognitive dissonance and continue to promote an outdated and potentially hazardous dietary recommendation based on an invalidated hypothesis. [Article]
  175. REVIEW
  176. Jones PJ1. Int J Clin Pract Suppl. 2009 Oct;(163):1-8, 28-36. doi: 10.1111/j.1742-1241.2009.02136.x. Dietary cholesterol and the risk of cardiovascular disease in patients: a review of the Harvard Egg Study and other data
    It is now acknowledged that the original studies purporting to show a linear relation between cholesterol intake and coronary heart disease (CHD) may have contained fundamental study design flaws, including conflated cholesterol and saturated fat consumption rates and inaccurately assessed actual dietary intake of fats by study subjects.[Abstract]
  177. OTHER
  178. [No authors listed] Int J Epidemiol. 1994 Jun;23(3):505-16. Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project
    This analysis has shown that accepted cardiovascular mortality risk factors measured cross-sectionally at the population level do not reflect well the variation in mortality between populations.[Abstract]
  179. Small dense LDL

    REVIEW
  180. Toth PP1. Curr Vasc Pharmacol. 2014;12(4):653-7. Insulin resistance, small LDL particles, and risk for atherosclerotic disease
    Among the most important risk factors patients afflicted with IR develop is the so-called atherogenic lipid triad: large numbers of small, dense low-density lipoprotein (sdLDL) particles, hypertriglyceridemia, and low serum concentrations of high-density lipoprotein cholesterol. Numerous small studies suggest that sdLDL is highly correlated with cardiovascular events. [Abstract]
  181. REVIEW
  182. Rizzo M1, Berneis K. Diabetes Metab Res Rev. 2007 Jan;23(1):14-20. Small, dense low-density-lipoproteins and the metabolic syndrome
    Small, dense low-density-lipoproteins (LDL) are associated with increased risk for cardiovascular diseases and diabetes mellitus and a reduction in LDL size has been reported in patients with coronary and non-coronary forms of atherosclerosis. LDL size has been accepted as an important predictor of cardiovascular events and progression of coronary artery disease as well as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III.[Abstract]
  183. REVIEW
  184. Rizzo M1, Berneis K. Int J Cardiol. 2006 Feb 15;107(2):166-70. Should we measure routinely the LDL peak particle size?
    LDL size seems also to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Since the therapeutic modulation of small, dense LDL particles is of great benefit in reducing the atherosclerotic risk, the LDL size measurement should be extended to patients at high risk of coronary artery disease as much as possible.[Abstract]
  185. Statines verhogen risico op diabetes type 2

    META
  186. Preiss D1, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
    In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.[Article]
  187. META
  188. Navarese EP1, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Am J Cardiol. 2013 Apr 15;111(8):1123-30. doi: 10.1016/j.amjcard.2012.12.037. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
    In conclusion, different types and doses of statins show different potential to increase the incidence of DM..[Abstract]
  189. META
  190. Danaei G1, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Diabetes Care. 2013 May;36(5):1236-40. doi: 10.2337/dc12-1756. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival
    In this sample of the general population, statin therapy was associated with 14% increased risk of type 2 diabetes.[Article]
  191. Statines Verlagen testosteron

    META
  192. Schooling CM1, Au Yeung SL, Freeman G, Cowling BJ. BMC Med. 2013 Feb 28;11:57. doi: 10.1186/1741-7015-11-57. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials
    Statins may partially operate by lowering testosterone. Whether this is a detrimental side effect or mode of action warrants investigation given the potential implications for drug development and prevention of non-communicable chronic diseases.[Article]
  193. TG / HDL-c ratio

    COMPARATIVE
  194. Boizel R1, Benhamou PY, Lardy B, Laporte F, Foulon T, Halimi S. Diabetes Care. 2000 Nov;23(11):1679-85. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels
    The ratio was > 1.33 in 90% of the patients with small LDL particles (95% CI 79.3-100) and 16.5% of those with larger LDL particles. A cutoff point of 1.33 for the TG-to-HDL cholesterol ratio distinguishes between patients having small LDL values better than TG cutoff of 1.70 and 1.45 mmol/l. The TG-to-HDL cholesterol ratio may be related to the processes involved in LDL size pathophysiology and relevant with regard to the risk of clinical vascular disease. It may be suitable for the selection of patients needing an earlier and aggressive treatment of lipid abnormalities.[Article]
  195. REVIEW
  196. Nesto RW1. Am J Cardiovasc Drugs. 2005;5(6):379-87. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome
    Small, dense, LDL-C particles are also highly atherogenic as they are more likely to form oxidized LDL and are less readily cleared. Insulin resistance, which is central to the metabolic syndrome and type 2 diabetes mellitus, leads to high levels of very low-density lipoprotein (VLDL), which contain a high concentration of triglycerides, resulting in high serum triglyceride levels and low serum HDL-C levels.[Abstract]
  197. OTHER
  198. King RI1, Florkowski CM, Yeo J, Walmsley TA, Shand BI, Scott RS, George PM. Ann Clin Biochem. 2011 Mar;48(Pt 2):166-9. doi: 10.1258/acb.2010.010185. What is the best predictor of the atherogenic LDL subclass phenotype ‘pattern B’ in patients with type 2 diabetes mellitus?
    The atherogenic lipoprotein phenotype ‘pattern B’ comprises a predominance of small-dense low-density lipoprotein (sdLDL). Direct measurement of sdLDL provided the most specific predictor of ‘pattern B’ phenotype, whereas triglyceride:HDL-C ratio or triglycerides alone, parameters readily available in most laboratories, were the best predictors by ROC analysis.[Article]
  199. OTHER
  200. de Giorgis T1, Marcovecchio ML, Di Giovanni I, Giannini C, Chiavaroli V, Chiarelli F, Mohn A. Eur J Endocrinol. 2013 Dec 21;170(2):173-80. doi: 10.1530/EJE-13-0452. Triglycerides-to-HDL ratio as a new marker of endothelial dysfunction in obese prepubertal children
    This study confirms the reliability of the TG:HDL-C ratio as a useful marker of cardiovascular risk. Interestingly, our results underline that the TG:HDL-C ratio is directly related with early signs of vascular damage already present in prepubertal children..[Article]
  201. OTHER
  202. Maruyama C1, Imamura K, Teramoto T.`J Atheroscler Thromb. 2003;10(3):186-91. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia
    Seventy-five percent of the Small LDL group had TG/HDL-C ratios higher than 0.9 using mmol/L or 2.0 using mg/dL, while only 25% of the normal LDL group had ratios above the levels (p = 0.0013). A combined parameter, the TG/HDL-C ratio, is beneficial for assessing the presence of small LDL.[Article]
  203. OTHER
  204. Burns SF1, Lee SJ, Arslanian SA. J Pediatr. 2012 Dec;161(6):991-6. doi: 10.1016/j.jpeds.2012.06.013. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth
    TG/HDL ratio and non-HDL cholesterol can identify overweight youth with atherogenic LDL particles. These easily obtained clinical lipid markers, in combination with body mass index and waist circumference, could be cost effective, in observational or interventional studies, for screening and follow-up of youth at heightened risk for atherogenic LDL.[Article]
  205. Yoga

    META
  206. Cramer H1, Lauche R2, Haller H2, Steckhan N3, Michalsen A4, Dobos G2. Int J Cardiol. 2014 May 1;173(2):170-83. doi: 10.1016/j.ijcard.2014.02.017. Effects of yoga on cardiovascular disease risk factors: a systematic review and meta-analysis
    This meta-analysis revealed evidence for clinically important effects of yoga on most biological cardiovascular disease risk factors. Despite methodological drawbacks of the included studies, yoga can be considered as an ancillary intervention for the general population and for patients with increased risk of cardiovascular disease.[Abstract]
  207. Eieren

    META
  208. Rong Y1, Chen L, Zhu T, Song Y, Yu M, Shan Z, Sands A, Hu FB, Liu L. BMJ. 2013 Jan 7;346:e8539. doi: 10.1136/bmj.e8539. Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies
    Higher consumption of eggs (up to one egg per day) is not associated with increased risk of coronary heart disease or stroke. The increased risk of coronary heart disease among diabetic patients and reduced risk of hemorrhagic stroke associated with higher egg consumption in subgroup analyses warrant further studies.[Article]
  209. RCT
  210. Mutungi G1, Ratliff J, Puglisi M, Torres-Gonzalez M, Vaishnav U, Leite JO, Quann E, Volek JS, Fernandez ML. J Nutr. 2008 Feb;138(2):272-6. Dietary cholesterol from eggs increases plasma HDL cholesterol in overweight men consuming a carbohydrate-restricted diet
    These results suggest that including eggs in a CRD results in increased HDL-C while decreasing the risk factors associated with MetS.[Article]
  211. RCT
  212. Katz DL1, Gnanaraj J2, Treu JA3, Ma Y3, Kavak Y3, Njike VY3. Am Heart J. 2015 Jan;169(1):162-9. doi: 10.1016/j.ahj.2014.10.001. Effects of egg ingestion on endothelial function in adults with coronary artery disease: a randomized, controlled, crossover trial
    We found no evidence of adverse effects of daily egg ingestion on any cardiac risk factors in adults with CAD over a span of 6 weeks.[Abstract]
  213. Soja nadelen

    REVIEW
  214. Liener IE. Crit Rev Food Sci Nutr. 1994;34(1):31-67. Implications of antinutritional components in soybean foods
    Other diverse but ill-defined factors appear to increase the requirements for vitamins A, B12, D, and E.[Abstract]
  215. Gilani GS, Cockell KA, Sepehr E. J AOAC Int. 2005 May-Jun;88(3):967-87. Effects of antinutritional factors on protein digestibility and amino acid availability in foods
    The presence of high levels of dietary trypsin inhibitors from soybeans, kidney beans, or other grain legumes can cause substantial reductions in protein and amino acid digestibilities (up to 50%) in rats and pigs.[Abstract]
  216. Lönnerdal B, Cederblad A, Davidsson L, Sandström B. Am J Clin Nutr. 1984 Nov;40(5):1064-70. The effect of individual components of soy formula and cows’ milk formula on zinc bioavailability
    Phytate was found to have a strong inhibitory effect on zinc absorption; addition of phytate to cows’ milk formula (yielding a phytate concentration similar to that of soy formula) resulted in a decrease in zinc absorption from 31 to 16% similar to the absorption for soy formula (14%). .[Article]
  217. Doerge DR, Sheehan DM. Environ Health Perspect. 2002 Jun;110 Suppl 3:349-53. Goitrogenic and estrogenic activity of soy isoflavones
    We then focus on evidence from animal and human studies suggesting a link between soy consumption and goiter, an activity independent of estrogenicity. Iodine deficiency greatly increases soy antithyroid effects, whereas iodine supplementation is protective. Thus, soy effects on the thyroid involve the critical relationship between iodine status and thyroid function.[Article]

  218. .[Abstract]

  219. .[Abstract]

  220. .[Abstract]

  221. .[Abstract]

Behandeling menopauzeklachten met cimicifuga (black cohosh)

    Menopause symptoms

    META
  1. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Altern Ther Health Med. 2010 Jan-Feb;16(1):36-44. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis
    Preparations containing black cohosh improved these symptoms overall by 26% (95% confidence interval 11%-40%); there was, however, significant heterogeneity between these trials.[Abstract]
  2. RCT
  3. Ross SM. Holist Nurs Pract. 2012 Jan-Feb;26(1):58-61. doi: 10.1097/HNP.0b013e31823d1f67. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms
    This clinical study confirmed previous results, which clearly indicate the efficacy and tolerability of this proprietary black cohosh extract (Remifemin) in addressing menopausal symptoms, particularly hot flashes.[Abstract]
  4. Sammartino A, Tommaselli GA, Gargano V, di Carlo C, Attianese W, Nappi C. Gynecol Endocrinol. 2006 Nov;22(11):646-50. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climacteric-related symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled trial
    The combination of these molecules can guarantee a better reduction of postmenopausal symptoms over a 24-h period.[Abstract]
  5. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer Ch, Birkhäuser M. Maturitas. 2005 Aug 16;51(4):397-404. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical tria
    The results indicate a superiority of the tested Cimicifuga racemosa extract compared to placebo in patients with menopausal disorders of at least moderate intensity according to a Kupperman Index > or =20, but not in the intention-to-treat population as a whole.[Abstract]
  6. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Gynecol Endocrinol. 2005 Jan;20(1):30-5. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol
    CR (40 mg/day) may be a valid alternative to low-dose TTSE2 in the management of climacteric complaints in those women who cannot be treated with or just refuse conventional strategies.[Abstract]
  7. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Obstet Gynecol. 2005 May;105(5 Pt 1):1074-83.Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms
    This isopropanolic extract of black cohosh root stock is effective in relieving climacteric symptoms, especially in early climacteric women.[Abstract]
  8. Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z, Geng L, Hu L, Jiao C, Liske E. Maturitas. 2007 Sep 20;58(1):31-41. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone
    The efficacy of iCR (medicinal product Remifemin) is as good as tibolone for the treatment of climacteric complaints, even for moderate to severe symptoms, whereby iCR is clearly superior regarding the safety profile.[Abstract]
  9. MULTI CENTER
  10. Drewe J, Zimmermann C, Zahner C. Phytomedicine. 2013 Jun 15;20(8-9):659-66. doi: 10.1016/j.phymed.2013.02.012. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints–an observational study.
    This observational study demonstrated that treatment with CR in unselected patients with climacteric complaints under the conditions of daily practice resulted in a significant improvement of menopausal symptoms assessed by the total KMI score and its sub-item scores with an effect size similar to that in a previous randomized, controlled clinical trial.[Abstract]
  11. CLINICAL
  12. Juliá Mollá MD, García-Sánchez Y, Romeu Sarri A, Pérez-lópez FR. Gynecol Endocrinol. 2009 Jan;25(1):21-6. doi: 10.1080/09513590802404005. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women
    CR treatment increased both global quality of life and the four domains of the Cervantes HR-QoL scale, being an effective treatment to reduce symptoms in post-menopausal woman with elevated body weight.[Abstract]
  13. REVIEW
  14. Wuttke W, Jarry H, Haunschild J, Stecher G, Schuh M, Seidlova-Wuttke D. J Steroid Biochem Mol Biol. 2014 Jan;139:302-10. doi: 10.1016/j.jsbmb.2013.02.007. The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa)
    These finding strengthens the role of CR extracts as substitutes for HRT. [Abstract]
  15. Cimicifuga + hypericum

    RCT
  16. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Obstet Gynecol. 2006 Feb;107(2 Pt 1):247-55. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial.
    This fixed combination of black cohosh and St. John’s wort is superior to placebo in alleviating climacteric complaints, including the related psychological component.[Abstract]
  17. Chung DJ, Kim HY, Park KH, Jeong KA, Lee SK, Lee YI, Hur SE, Cho MS, Lee BS, Bai SW, Kim CM, Cho SH, Hwang JY, Park JH. Yonsei Med J. 2007 Apr 30;48(2):289-94. Black cohosh and St. John’s wort (GYNO-Plus) for climacteric symptoms
    Black cohosh and St. John’s wort combination was found to be effective in alleviating climacteric symptoms and might provide benefits to lipid metabolism.[Article]
  18. Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Maturitas. 2007 Aug 20;57(4):405-14. Epub 2007 Jun 21. Black cohosh with or without St. John’s wort for symptom-specific climacteric treatment–results of a large-scale, controlled, observational study
    The results support the effectiveness and tolerability profiles of two Black cohosh-based therapies for menopausal symptoms in general practice. The fixed combination of Black cohosh and St. John’s wort was superior to Black cohosh alone in alleviating climacteric mood symptoms.[Abstract]
  19. RCT – SYMPTOMS + FLUOXETINE
  20. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Adv Ther. 2007 Mar-Apr;24(2):448-61. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial
    Compared with fluoxetine, black cohosh is more effective for treating hot flushes and night sweats. On the other hand, fluoxetine is more effective in improvements shown on Beck’s Depression Scale.[Abstract]
  21. Safety

    META
  22. Naser B, Schnitker J, Minkin MJ, de Arriba SG, Nolte KU, Osmers R. Menopause. 2011 Apr;18(4):366-75. doi: 10.1097/gme.0b013e3181fcb2a6. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract
    The results of this meta-analysis of five randomized, double-blind, and controlled clinical trials showed no evidence that iCR has any adverse effect on liver function.[Abstract]
  23. RCT
  24. Lundström E, Hirschberg AL, Söderqvist G. Maturitas. 2011 Dec;70(4):361-4. doi: 10.1016/j.maturitas.2011.08.009. Digitized assessment of mammographic breast density–effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo
    Digitized mammographic breast density is a highly sensitive method confirming significant increase in density by standard E2/NETA treatment and to a lesser extent by tibolone, whereas black cohosh does not influence mammographic breast density during six months treatment.[Abstract]
  25. CLINICAL
  26. Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B Menopause. 2007 Jan-Feb;14(1):89-96. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women
    The findings suggest that the isopropanolic extract of black cohosh does not cause adverse effects on breast tissue. Furthermore, our data do not indicate to any endometrial or general safety concerns during 6 months of treatment.[Abstract]
  27. Nasr A, Nafeh H. Fertil Steril. 2009 Nov;92(5):1780-2. doi: 10.1016/j.fertnstert.2009.05.038. Influence of black cohosh (Cimicifuga racemosa) use by postmenopausal women on total hepatic perfusion and liver functions
    Because no significant changes in total hepatic blood flow or any of the liver functions tested were reported, we concluded that use of C. racemosa for 1 year by healthy postmenopausal women without evidence of liver disease does not seem to influence the liver.[Abstract]
  28. Wuttke W, Seidlová-Wuttke D, Gorkow C. Maturitas. 2003 Mar 14;44 Suppl 1:S67-77. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers
    The results concerning climacteric complaints and on bone metabolism indicate an equipotent effect of CR BNO 1055 in comparison to 0.6 mg CE per day. It is proposed that CR BNO 1055 contains substances with SERM activity, i.e. with desired effects in the brain/hypothalamus, in the bone and in the vagina, but without exerting uterotrophic effects.[Abstract]
  29. Radowicki S, Skórzewska K, Rudnicka E, Szlendak-Sauer K, Wierzba W. Ginekol Pol. 2006 Sep;77(9):678-83. Effectiveness and safety of the treatment of menopausal syndrome with Cimicifuga racemosa dry extract
    Cimicifuga racemosa dry extract was an effective and safe therapy of climacteric women with contraindications to hormonal replacement therapy.[Abstract]
  30. MULTI CENTER
  31. Raus K, Brucker C, Gorkow C, Wuttke W. Menopause. 2006 Jul-Aug;13(4):678-91. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055
    The lack of endometrial proliferation and improvement of climacteric complaints as well as only few gynecologic organ-related adverse events are reported for the first time after a treatment period of 1 year. Due to the improved benefit:risk ratio, it must be assumed that the Cimicifuga racemosa special extract BNO 1055 is a safe alternative for treatment of climacteric complaints.[Abstract]
  32. REVIEW
  33. McKenna DJ, Jones K, Humphrey S, Hughes K. Altern Ther Health Med. 2001 May-Jun;7(3):93-100. Black cohosh: efficacy, safety, and use in clinical and preclinical applications
    The safety profile of black cohosh is positive, with low toxicity, few and mild side effects, and good tolerability. In European phytotherapy, Remifemin is commonly prescribed as an effective alternative to hormone replacement therapy for menopause.[Abstract]
  34. Wuttke W, Jarry H, Haunschild J, Stecher G, Schuh M, Seidlova-Wuttke D. J Steroid Biochem Mol Biol. 2014 Jan;139:302-10. doi: 10.1016/j.jsbmb.2013.02.007. E vThe non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa)
    Extracts of the rhizome of black cohosh (Cimicifuga racemosa=CR) did not bind to estrogen receptors and were shown to be devoid of estrogenic effects on mammary cancer cells in vitro and on mammary gland and uterine histology in ovariectomized rats.[Abstract]
  35. Osteoporosis

    CLINICAL
  36. García-Pérez MA, Pineda B, Hermenegildo C, Tarín JJ, Cano A. Fertil Steril. 2009 Apr;91(4 Suppl):1347-50. doi: 10.1016/j.fertnstert.2008.03.042. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line
    Postmenopausal women treated with an isopropanolic extract of Cimicifuga racemosa underwent a decrease in the urinary concentration of N-telopeptides, a marker of bone resorption, and an increase in alkaline phosphatase, a marker of bone formation, at the third month of therapy.[Abstract]
  37. Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A, Zhang H, Lambert GH, Reeser KA, Wisbey JA. Cancer Invest. 2004;22(4):515-21. Pilot evaluation of black cohosh for the treatment of hot flashes in women
    Black cohosh appeared to reduce hot flashes and had a low toxicity. The efficacy found in this trial seems to be more than would be expected by a placebo effect (20%-30% hot flash reduction in previous trials). [Abstract]
  38. Liske E, Hänggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW. J Womens Health Gend Based Med. 2002 Mar;11(2):163-74. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect
    The higher dose did not exert a significantly greater effect on any end point. Thus, the currently recognized standard dose of the isopropanolic aqueous C. racemosa extract should be preferred over the higher dose.[Abstract]
  39. Nog niet gebruikt

    REVIEW
  40. Reinhard-Hennch B, Strowitzki T, von Hagens C. Gynakol Geburtshilfliche Rundsch. 2006;46(4):197- Complementary and alternative therapies for climacteric symptom
    Lifestyle modifications, Cimicifuga and phytoestrogens may relieve climacteric symptoms. Phytoestrogens and Cimicifuga should not be given to breast cancer survivors.[Abstract]

  41. .[Abstract]

Behandeling menopauzeklachten met Rode klaver

    Menopauzeklahten

    META
  1. Coon JT, Pittler MH, Ernst E. Phytomedicine. 2007 Feb;14(2-3):153-9. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis
    There is evidence of a marginally significant effect of T. pratense isoflavones for treating hot flushes in menopausal women.[Abstract]
  2. RCT
  3. Lipovac M, Chedraui P, Gruenhut C, Gocan A, Kurz C, Neuber B, Imhof M. Gynecol Endocrinol. 2012 Mar;28(3):203-7. doi: 10.3109/09513590.2011.593671 The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women
    Red clover isoflavone supplementation was more effective than placebo in reducing daily vasomotor frequency and overall menopausal intensity in postmenopausal women.[Abstract]
  4. Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G. Gynecol Endocrinol. 2005 Nov;21(5):257-64. he effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study
    Compared with placebo, red clover isoflavone supplementation in postmenopausal women significantly decreased menopausal symptoms and had a positive effect on vaginal cytology and triglyceride levels.[Abstract]
  5. CLINICAL
  6. van de Weijer PH, Barentsen R. Maturitas. 2002 Jul 25;42(3):187-93. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo
    In this study, treatment with 80 mg isoflavones (Promensil) per day resulted in a significant reduction in hot flushes from baseline. At the end of the study there was a significant decrease in hot flushes of 44% between the active and placebo group, demonstrating the effectiveness of Promensil in the management of hot flushes.[Abstract]
  7. REVIEW
  8. Huntley AL1, Ernst E. Menopause. 2003 Sep-Oct;10(5):465-76. A systematic review of herbal medicinal products for the treatment of menopausal symptoms
    The studies involving red clover suggest it may be of benefit for more severe menopausal symptoms.[Abstract]
  9. Angst en depressie

    RCT
  10. Lipovac M, Chedraui P, Gruenhut C, Gocan A, Stammler M, Imhof M. Maturitas. 2010 Mar;65(3):258-61. doi: 10.1016/j.maturitas.2009.10.014. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts
    Red clover derived isoflavones (MF11RCE) were effective in reducing depressive and anxiety symptoms among postmenopausal women.[Abstract]
  11. Bloedvetten

    CLINICAL
  12. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. Menopause. 2001 Jul-Aug;8(4):259-65. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism
    These results show that the administration of an isoflavone combination extracted from red clover was associated with a significant increase in high-density lipoprotein cholesterol, a significant fall in apolipoprotein B, and a significant increase in the predominantly cortical bone of the proximal radius and ulna after 6 months of treatment.[Abstract]
  13. RCT
  14. Terzic MM, Dotlic J, Maricic S, Mihailovic T, Tosic-Race B. J Obstet Gynaecol Res. 2009 Dec;35(6):1091-5. doi: 10.1111/j.1447-0756.2009.001059.x. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women
    Red clover phytoestrogen supplementation in postmenopausal women had favorable metabolic effects on serum lipids. Furthermore, red clover phytoestrogens have no side-effects and can be considered safe.[Abstract]
  15. Veiligheid

    MULTIUCENTER RCT
  16. Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA, Tidy A. Menopause Int. 2008 Mar;14(1):6-12. doi: 10.1258/mi.2007.007033. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer
    This three-year study supports the growing body of evidence that treatment with red clover isoflavones is safe and well tolerated in healthy women. Supplements containing red clover isoflavones did not adversely affect breast density, skeletal strength or cardiovascular status.[Abstract]
  17. Powles T. Breast Cancer Res. 2004;6(3):140-2. Epub 2004 Apr 6. Isoflavones and women’s health
    A placebo-controlled clinical trial [ISRCTN42940165] of red clover is reported in this issue of Breast Cancer Research and shows that these phytoestrogens do not cause any oestrogenic increase in breast density, which would indicate that they are unlikely to cause an increased risk of breast cancer.[Article]
  18. RCT
  19. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Breast Cancer Res. 2004;6(3):R170-9. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial
    In contrast to studies showing that conventional hormone replacement therapies increase mammographic breast density, the isoflavone supplement did not increase mammographic breast density in this population of women.[Article]
  20. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, Hedayat S, Nikolic D, Krause EC, Piersen CE, Bolton JL, Pauli GF, Farnsworth NR. Menopause. 2009 Nov-Dec;16(6):1156-66. doi: 10.1097/gme.0b013e3181ace49b. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial
    Safety monitoring indicated that chemically and biologically standardized extracts of black cohosh and red clover were safe during daily administration for 12 months.[Article]
  21. Imhof M, Gocan A, Reithmayr F, Lipovac M, Schimitzek C, Chedraui P, Huber J. Maturitas. 2006 Aug 20;55(1):76-81 Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women
    MF11RCE exerts a moderate effect on testosterone levels in postmenopausal women, while estradiol levels remained unchanged. The observed reduction of endometrial thickness provides further support for a safe role for isoflavones in terms of endometrial hyperplasia.[Abstract]
  22. REVIEW
  23. Booth NL, Piersen CE, Banuvar S, Geller SE, Shulman LP, Farnsworth NR. Menopause. 2006 Mar-Apr;13(2):251-64. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review
    Furthermore, the safety of use of red clover isoflavone supplements in patients with breast or endometrial cancer has not been established.[Abstract]
  24. CASE
  25. Orr A, Parker R. Menopause Int. 2013 Sep;19(3):133-4. doi: 10.1177/1754045313502473. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate
    The case report discusses a very serious interaction between red clover and methotrexate not previously documented.[Abstract]

  26. .[Abstract]

Behandeling menopauzeklachten met Hypericum

    Depressie

    REVIEW
  1. Bromberger JT1, Kravitz HM. Obstet Gynecol Clin North Am. 2011 Sep;38(3):609-25. doi: 10.1016/j.ogc.2011.05.011. Mood and menopause: findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years
    Women are twice as likely as men to suffer from depressive symptoms/disorder. We found that risk for high depressive symptoms and disorder is greater during and possibly after the menopausal transition.[Article]
  2. Freeman EW. Menopause. 2010 Jul;17(4):823-7. doi: 10.1097/gme.0b013e3181db9f8b. Associations of depression with the transition to menopause
    Women with a history of depression are nearly five times more likely to have a diagnosis of major depression in the menopausal transition, whereas women with no history of depression are two to four times more likely to report depressed mood compared with premenopausal women.[Abstract]
  3. META
  4. Linde K1, Mulrow CD. Cochrane Database Syst Rev. 2000;(2):CD000448. St John’s wort for depression
    There is evidence that extracts of hypericum are more effective than placebo for the short-term treatment of mild to moderately severe depressive disorders.[Abstract]
  5. Kasper S1, Gastpar M, Möller HJ, Müller WE, Volz HP, Dienel A, Kieser M. Int Clin Psychopharmacol. 2010 Jul;25(4):204-13. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression
    In conclusion, WS 5570 exhibits substantially lower incidence rates of adverse events than paroxetine and other SSRIs.[Abstract]
  6. Rahimi R1, Nikfar S, Abdollahi M. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):118-27. doi: 10.1016/j.pnpbp.2008.10.018. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis
    Hypericum does not differ from SSRIs according to efficacy and adverse events in MDD. Lower withdrawal from study due to adverse events by Hypericum is an advantage in management of MDD.[Abstract]
  7. HYPERIPLANT®tabletten 60 / 90 / 100 / 120 filmomhulde tabletten
    Bij milde tot matige depressieve klachten.[Article]
  8. Menopauzeklachten

    COMPARITIVE
  9. Fahami F1, Asali Z, Aslani A, Fathizadeh N. Iran J Nurs Midwifery Res. 2010 Fall;15(4):202-7. A comparative study on the effects of Hypericum Perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers
    With regard to the effects of Hypericum Perforatum and Passion Flower on treating menopause precocious symptoms (vasomotor signs, insomnia, depression, anger, headache, etc.), these two herbs can be used as an alternative treatment for individuals who cannot, whatsoever, use hormone therapy.[Article]
  10. META
  11. Liu YR1, Jiang YL, Huang RQ, Yang JY, Xiao BK, Dong JX. Climacteric. 2013 Dec 27. [ Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety
    extracts of Hypericum perforatum L. proved to be more effective than placebo in the treatment of menopause.[Abstract]
  12. RCT
  13. Abdali K, Khajehei M, Tabatabaee HR. Menopause. 2010 Mar;17(2):326-31. doi: 10.1097/gme.0b013e3181b8e02d. Effect of St John’s wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study
    St John’s wort can be used as an effective treatment for the vasomotor symptoms of perimenopausal or postmenopausal women.[Abstract]
  14. Al-Akoum M, Maunsell E, Verreault R, Provencher L, Otis H, Dodin S. Menopause. 2009 Mar-Apr;16(2):307-14. doi: 10.1097/gme.0b013e31818572a0. Effects of Hypericum perforatum (St. John’s wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial
    Hypericum perforatum may improve quality of life in ways that are important to symptomatic perimenopausal women, but these results need to be confirmed by a larger clinical trial.[Abstract]
  15. van Die MD, Bone KM, Burger HG, Reece JE, Teede HJ. J Altern Complement Med. 2009 Sep;15(9):1045-8. doi: 10.1089/acm.2008.0539. Effects of a combination of Hypericum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis.
    These results suggest a potentially significant clinical application for this phytotherapeutic combination in PMS-like symptoms among perimenopausal women. Further research is warranted through a randomized, controlled trial dedicated to investigation of these symptoms.[Abstract]
  16. CLINICAL
  17. Grube B, Walper A, Wheatley D. Adv Ther. 1999 Jul-Aug;16(4):177-86. St. John’s Wort extract: efficacy for menopausal symptoms of psychological origin
    Climacteric complaints diminished or disappeared completely in the majority of women (76.4% by patient evaluation and 79.2% by physician evaluation). Of note, sexual well-being also improved after treatment with St. John’s Wort extract.[Abstract]
  18. Veiligheid

    META
  19. Kasper S1, Gastpar M, Möller HJ, Müller WE, Volz HP, Dienel A, Kieser M. Int Clin Psychopharmacol. 2010 Jul;25(4):204-13. Better tolerability of St. John’s wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression
    In conclusion, WS 5570 exhibits substantially lower incidence rates of adverse events than paroxetine and other SSRIs.[Abstract]
  20. REVIEW
  21. Schulz V. Phytomedicine. 2006 Feb;13(3):199-204. Safety of St. John’s Wort extract compared to synthetic antidepressants
    As with synthetic antidepressants, pharmacokinetic interactions may occur occasionally as a result of activity changes of drug-metabolising and drug-transporting proteins, especially CYP 3A4 and P-gp. Risks to the patient are not caused by SWE but by drugs with a narrow therapeutic range. [Abstract]
  22. Markowitz JS1, DeVane CL. Psychopharmacol Bull. 2001 Winter;35(1):53-64. The emerging recognition of herb-drug interactions with a focus on St. John’s wort (Hypericum perforatum)
    owever, available data from clinical studies and case reports suggests that St. John’s wort is unlikely to inhibit cytochrome P450 (CYP) 3A4 or 2D6, but is likely an inducer of CYP 3A4 and possibly the P-glycoprotein transporter.[Abstract]
  23. Zhou S1, Chan E, Pan SQ, Huang M, Lee EJ. J Psychopharmacol. 2004 Jun;18(2):262-76. Pharmacokinetic interactions of drugs with St John’s wort
    St John’s wort caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives.[Abstract]

  24. .[Abstract]

Chinese kruiden

    Dang Gui = Dong Quai = Angelica sinensis

    RCT
  1. Haines CJ, Lam PM, Chung TK, Cheng KF, Leung PC. Climacteric. 2008 Jun;11(3):244-51. doi: 10.1080/13697130802073029. A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women
    The frequency of mild, moderate and severe hot flushes decreased in both treatment and placebo groups, but Dang Gui Buxue Tang was statistically superior to placebo only in the treatment of mild hot flushes.[Abstract]
  2. Wang CC, Cheng KF, Lo WM, Law C, Li L, Leung PC, Chung TK, Haines CJ. Menopause. 2013 Feb;20(2):223-31. doi: 10.1097/gme.0b013e318267f64 A randomized, double-blind, multiple-dose escalation study of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) for moderate to severe menopausal symptoms and quality of life in postmenopausal women
    DBT preparations at 6.0 g/day significantly improve physical and psychological scores and significantly reduce vasomotor symptoms from baseline. The treatment was well tolerated, with no serious adverse events noted during the 12-week intervention period.[Abstract]
  3. CLINICAL
  4. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Fertil Steril. 1997 Dec;68(6):981-6. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial
    Used alone, dong quai does not produce estrogen-like responses in endometrial thickness or in vaginal maturation and was no more helpful than placebo in relieving menopausal symptoms.[Abstract]
  5. REVIEW
  6. Hook IL. J Ethnopharmacol. 2014 Feb 27;152(1):1-13. doi: 10.1016/j.jep.2013.12.018. Danggui to Angelica sinensis root: Are potential benefits to European women lost in translation? A review
    In spite of the potential activities associated with the traditional use of danggui, and the many trials using the Chinese system of ‘Zheng differentiation’, well-designed western-style clinical trials carried out using the authenticated, chemically standardized crude drug material to confirm clinical efficacy are in short supply. However increasing research into Angelica sinensis extracts and constituents shows that many of the traditional uses are not without scientific basis.[Abstract]
  7. RCT
  8. Kupfersztain C, Rotem C, Fagot R, Kaplan B. Clin Exp Obstet Gynecol. 2003;30(4):203-6. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report
    Treatment with Climex seems to be effective for menopausal symptoms without apparent major adverse effects. This hormone-free preparation may be used as an important modality for menopausal women with contraindications for hormone replacement therapy.[Abstract]
  9. Amsterdam JD1, Shults J, Soeller I, Mao JJ, Rockwell K, Newberg AB. Altern Ther Health Med. 2012 Sep-Oct;18(5):44-9. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study
    Chamomile may provide clinically meaningful antidepressant activity that occurs in addition to its previously observed anxiolytic activity.[Abstract]
  10. OTHER
  11. Lau CB1, Ho TC, Chan TW, Kim SC. Menopause. 2005 Nov-Dec;12(6):734-40. Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate?
    Because of the lack of clinical data demonstrating the potential side effects of dong quai, its use in herbal preparations for the treatment of peri- or postmenopausal symptoms, especially in women with breast cancer, warrants caution pending further study.[Abstract]
  12. Er-xian

    META
  13. Chen HY, Cho WC, Sze SC, Tong Y. Am J Chin Med. 2008;36(2):233-44. Treatment of menopausal symptoms with Er-xian decoction: a systematic review
    The results also indicated that the efficacy of EXD was better than the other non-menopausal hormone therapy (p<0.01), while there was no significant difference between the EXD and menopausal hormone therapy groups.[Abstract]
  14. RCT
  15. Zhong LL, Tong Y, Tang GW, Zhang ZJ, Choi WK, Cheng KL, Sze SC, Wai K, Liu Q, Yu BX. Menopause. 2013 Jul;20(7):767-76. doi: 10.1097/GME.0b013e31827cd3dd. A randomized, double-blind, controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in Hong Kong perimenopausal women
    The Chinese herbal formula EXD is superior to placebo in reducing the frequency and severity of hot flushes and in improving menopausal symptoms in Hong Kong perimenopausal women. It is well tolerated, with no serious adverse events noted during the study period.[Abstract]
  16. Jiawei Qing’e Fang

  17. Xia Y, Zhao Y, Ren M, Zhang J, Wang Y, Chang Y, Fu S, Fan G, Zhu Y, Huang Y, Gao X. Menopause. 2012 Feb;19(2):234-44. doi: 10.1097/gme.0b013e3182273177. A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing’e Fang) for hot flashes and quality of life in perimenopausal wome
    The Chinese herbal medicine preparation JQF was found to be superior to placebo in reducing hot flashes and improving menopausal symptoms in the vasomotor and physical aspects and might have a potential benefit in reducing TG levels. The herbal medicine preparation was well tolerated, with no serious adverse events noted during the study period.[Abstract]
  18. Wild Yam

    OTHER
  19. Wojcikowski K, Wohlmuth H, Johnson DW, Gobe G. Food Chem Toxicol. 2008 Sep;46(9):3122-31. doi: 10.1016/j.fct.2008.06.090. Dioscorea villosa (wild yam) induces chronic kidney injury via pro-fibrotic pathways
    Long term supplementation with D. villosa may be best avoided, especially in people with compromised renal function and in those who need to take other drugs which may alter kidney function.[Abstract]
  20. Nog niet gebruikte studies

    1. Mazaro-Costa R1, Andersen ML, Hachul H, Tufik S. J Sex Med. 2010 Nov;7(11):3695-714. doi: 10.1111/j.1743-6109.2010.01987.x. Medicinal plants as alternative treatments for female sexual dysfunction: utopian vision or possible treatment in climacteric women?
      Ferula hermonis, Angelica sinensis, and Gingko biloba may be suggested for arousal disorder studies. Cimicifuga racemosa, Trifolium pratense, and Vitex agnus-castus may be recommended for several FSD. Humulus lupulus and Tribulus terrestris may help with desire disorder studies. Lepidium meyenii should be studied further.[Abstract]

    2. .[Abstract]

    3. .[Abstract]

    4. .[Abstract]

    5. .[Abstract]

    6. .[Abstract]

    7. .[Abstract]

    8. .[Abstract]

    Nog niet gebruikt

      REVIEW
    1. Depypere HT1, Comhaire FH2. Maturitas. 2014 Feb;77(2):191-4. doi: 10.1016/j.maturitas.2013.11.001. Herbal preparations for the menopause: beyond isoflavones and black cohosh
      Randomized controlled trials (RCTs) find that the extracts of Mediterranean pine bark (Pycnogenol(®)), linseed, and Lepididium meyenii (Maca) reduce vasomotor symptoms.[Abstract]
    2. REVIEW
    3. Shin BC1, Lee MS, Yang EJ, Lim HS, Ernst E. BMC Complement Altern Med. 2010 Aug 6;10:44. doi: 10.1186/1472-6882-10-44.Maca (L. meyenii) for improving sexual function: a systematic review
      The results of our systematic review provide limited evidence for the effectiveness of maca in improving sexual function. However, the total number of trials, the total sample size, and the average methodological quality of the primary studies were too limited to draw firm conclusions. More rigorous studies are warranted.[Article]
    4. RCT
    5. Brooks NA1, Wilcox G, Walker KZ, Ashton JF, Cox MB, Stojanovska L. Menopause. 2008 Nov-Dec;15(6):1157-62. doi: 10.1097/gme.0b013e3181732953. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content
      Preliminary findings show that Lepidium meyenii (Maca) (3.5 g/d) reduces psychological symptoms, including anxiety and depression, and lowers measures of sexual dysfunction in postmenopausal women independent of estrogenic and androgenic activity.[Abstract]